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The Trials and Tribulations of 
Structure Assisted Design of KCa 
Channel Activators
Heesung Shim 1,2†, Brandon M. Brown 1†, Latika Singh 1, Vikrant Singh 1, James C. Fettinger 2, 
Vladimir Yarov-Yarovoy 3 and Heike Wulff 1*
1 Department of Pharmacology, School of Medicine, University of California, Davis, Davis, CA, United States, 2 Department 
of Chemistry, University of California, Davis, Davis, CA, United States, 3 Department of Physiology and Membrane Biology, 
School of Medicine, University of California, Davis, Davis, CA, United States
Calcium-activated K+ channels constitute attractive targets for the treatment of neurological 
and cardiovascular diseases. To explain why certain 2-aminobenzothiazole/oxazole-type 
KCa activators (SKAs) are KCa3.1 selective we previously generated homology models of 
the C-terminal calmodulin-binding domain (CaM-BD) of KCa3.1 and KCa2.3 in complex 
with CaM using Rosetta modeling software. We here attempted to employ this atomistic 
level understanding of KCa activator binding to switch selectivity around and design KCa2.2 
selective activators as potential anticonvulsants. In this structure-based drug design 
approach we used RosettaLigand docking and carefully compared the binding poses 
of various SKA compounds in the KCa2.2 and KCa3.1 CaM-BD/CaM interface pocket. 
Based on differences between residues in the KCa2.2 and KCa.3.1 models we virtually 
designed 168 new SKA compounds. The compounds that were predicted to be both 
potent and KCa2.2 selective were synthesized, and their activity and selectivity tested by 
manual or automated electrophysiology. However, we failed to identify any KCa2.2 selective 
compounds. Based on the full-length KCa3.1 structure it was recently demonstrated that 
the C-terminal crystal dimer was an artefact and suggested that the “real” binding pocket 
for the KCa activators is located at the S4-S5 linker. We here confirmed this structural 
hypothesis through mutagenesis and now offer a new, corrected binding site model for 
the SKA-type KCa channel activators. SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine) 
is binding in the interface between the CaM N-lobe and the S4-S5 linker where it makes 
van der Waals contacts with S181 and L185 in the S45A helix of KCa3.1.
Keywords: calcium-activated potassium channels, KCa3.1, KCa2.2, calmodulin binding domain, SKA-111, 
Rosetta, KCa activators
INTRODUCTION
Small- and intermediate-conductance calcium-activated potassium channels (KCa) are voltage 
independent and are gated by the binding of calcium to calmodulin, which functions as their calcium-
sensing beta subunit (Xia et al., 1998; Fanger et al., 1999). There are four members in the small- and 
intermediate-conductance KCa channel subfamily, the small-conductance KCa2.1, KCa2.2, and KCa2.3, 
collectively known as SK channels, and the intermediate-conductance KCa3.1, also known as IK 
(Kaczmarek et al., 2017). These tetrameric membrane proteins consist of four six-transmembrane 
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domains with their N- and C-termini positioned intracellularly. 
Calmodulin (CaM) is constitutively bound with its C-lobe to the 
calmodulin binding domain (CaM-BD) in the C-terminus of each 
KCa channel subunit and opens the channel when the N-lobe binds 
calcium following increases in intracellular calcium in the proximity 
of the channel (Xia et al., 1998; Lee and MacKinnon, 2018). KCa2/3 
channels are differentially expressed in the human body with KCa2 
channels primarily expressed in, but not limited to, the CNS and 
KCa3.1 primarily found in peripheral tissues, lymphocytes and 
red blood cells (Adelman et al., 2012; Wulff and Kohler, 2013). 
KCa2 channels mediate after hyperpolarization and regulate firing 
frequency in neurons (Adelman et al., 2012). KCa3.1, on the 
other hand, is responsible for generating the driving force for 
calcium influx in immune cells and contributes to the regulation 
of vascular tone via the vascular endothelium (Wulff and 
Kohler, 2013). These expression patterns make both KCa2 and 
KCa3.1 channels attractive pharmacological targets (Wulff and 
Zhorov, 2008). Specifically, activation of KCa2 channels has been 
proposed for the treatment of diseases characterized by increased 
neuronal excitability, like ataxia (Shakkottai et al., 2011; Kasumu 
et al., 2012) and epilepsy, whereas activation of KCa3.1 has been 
proposed as a treatment for hypertension (Wulff and Kohler, 
2013) and as a possible way to pharmacologically enhance 
anti-tumor T cell responses (Chandy and Norton, 2016). The 
idea behind the later hypothesis is that by enhancing K+ efflux 
and thus lowering intracellular K+ it might be possible to reset 
the “ionic checkpoint” and boost anti-tumor T cell functions 
in tumor infiltrating T cells, which have been shown to have 
increased intracellular K+ concentrations suppressing their ability 
to activate (Eil et al., 2016). In support of this exciting therapeutic 
postulate, it has recently been demonstrated that pharmacological 
KCa3.1 activation can restore the ability of cancer patient derived 
CD8+ T cells to chemotax (Chimote et al., 2018).
Identifying potent and selective KCa channel activators has been 
challenging. The first generation, which includes 1-EBIO, NS309 
(Strobaek et al., 2004), and SKA-31 (Sankaranarayanan et al., 2009), 
are relatively unselective and only display a 5–10-fold selectivity for 
KCa3.1 over KCa2 channels (Christophersen and Wulff, 2015). This 
lack of selectivity has led to CNS related side effects when trying to 
use KCa3.1 activation as a new, endothelial targeted antihypertensive 
approach (Radtke et al., 2013). The second generation of KCa 
channel activators, as exemplified by SKA-121 and SKA-111, are 
40–100-fold selective for KCa3.1 and were efficacious in lowering 
blood pressure in normotensive and hypertensive mice while 
avoiding KCa2 channel mediated side effects on the CNS and on 
heart rate because of the improvement in selectivity (Coleman et al., 
2014). For the development of our first and second generation KCa 
activators (the “SKA” compounds), we used a classical medicinal 
chemistry approach with no structural input during the structure 
activity optimization (Sankaranarayanan et al., 2009; Coleman 
et al., 2014). However, more recently, following the publication 
(Zhang et al., 2013) of the crystal structure of the KCa2.2 CaM-BD 
in complex with CaM and containing NS309 (pdb: 4J9Z), we 
generated homology models of the KCa3.1 and KCa2.3 CaM-BD in 
complex with CaM using the Rosetta molecular modeling suite 
and RosettaLigand for compound docking (Brown et al., 2017). 
Combining structural modeling and site-directed mutagenesis 
we determined that S372 in KCa3.1 (or the corresponding S632 
in KCa2.3) is crucial for the activity of all 2-aminobenzothiazole/
oxazole-type KCa activators, which are further stabilized by an 
extensive hydrogen bond network including E295, N300, R362 
in KCa3.1 and M51 and E54 in calmodulin. Based on our findings 
we suggested that R362, a residue which is at the center of this 
network in the KCa3.1 but not the KCa2.3 models, is responsible 
for the 5–10-fold selectivity of these compounds for KCa3.1 over 
KCa2.3 (Brown et al., 2017).
In the current work we set out to use our atomistic level 
understanding of KCa activator binding to develop a third 
generation of KCa channel activators; this time with selectivity for 
KCa2.2 over KCa3.1. In this structure-based drug design approach 
we again used Rosetta ligand docking and carefully compared 
the binding poses of 2-aminobenzothiazole/oxazole-type KCa 
activators in the KCa2.2 and KCa3.1 CaM-BD/CaM interface 
pocket. Based on differences between residues in the KCa2.2 
and KCa.3.1 models we manually designed 168 new virtual SKA 
compounds and tried to predict whether the compounds would 
show selectivity for KCa2.2 based on the computational docking 
models. The most promising compounds were synthesized, 
and their potency and selectivity for KCa2.2, and KCa3.1 tested 
by manual or automated electrophysiology. However, despite 
all these efforts, we failed to identify any KCa2.2 selective 
compounds and recently learned from the full-length cryo-EM 
structure of KCa3.1 published by the MacKinnon group (Lee and 
MacKinnon, 2018), that the C-terminal crystal was an artefact. 
Based on the full-length structure it was suggested that the “real” 
binding pocket for the KCa activators is located between the S4-S5 
linker and the CaM N-lobe (Lee and MacKinnon, 2018). We 
here confirmed this structural hypothesis through mutagenesis 
and now offer a new, corrected binding site model for the SKA-
type KCa channel activators. We hope that our findings provide 
a cautionary tale for the field in warning against some of the 
pitfalls in structure-based drug design.
MATERIAL AND METHODS
Molecular Modeling
We previously described the generation of models (Brown et al., 
2017) of the KCa3.1 and KCa2.3 C-terminal CaM-binding domain in 
complex with CaM with Rosetta computational modeling software 
(Rohl et al., 2004; Bender et al., 2016; Alford et al., 2017) using 
the x-ray structure of the KCa2.2 channel CaM-binding domain in 
complex with CaM and NS309 (Zhang et al., 2013) (pdb id: 4J9Z) 
as a template. We also previously provided a detailed description 
(Brown et al., 2017) of the procedure for ligand docking using the 
RosettaLigand docking application (Meiler and Baker, 2006; Davis and 
Baker, 2009; Bender et al., 2016) in the Rosetta program suite, version 
3.7. Briefly, for this study, ligand conformers of variously substituted 
benzothiazoles/oxazoles were generated using Open Eye OMEGA 
software version 2.5.1.4 (OpenEye Scientific Software, Santa Fe, 
NM; http://www.eyesopen.com) (Hawkins et al., 2010; Hawkins 
and Nicholls, 2012; OEChem v OpenEye Scientific Software, Inc.), 
randomly placed within the binding pocket and then taken through 
the three stages of the RosettaLigand modeling which progresses 
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from low-resolution conformational sampling and scoring to full 
atom optimization using Rosetta’s all-atom energy function. A total 
of 10,000 models were generated for each virtual compound, the 
top 1,000 models with the lowest total energy score were selected, 
and the top 10 models with the lowest binding energy were 
identified, manually inspected for ligand/channel interactions and 
convergence between the KCa2.2 and the KCa3.1 model compared. 
A model was considered converged if the top 10 models overlaid.
Cryo-EM structures of the full length KCa3.1 channel (Lee and 
MacKinnon, 2018) in two open states and one closed state (pdb id: 
6CNN, 6CNO, 6CNM) were refined using the Rosetta cryo-EM 
refinement protocol (Wang et al., 2016) (Cryo-EM density map, 
Rosetta version 3.8) and the models with the lowest energy scores 
were chosen for docking of SKA-111. All molecular graphics of 
ligand, KCa channel C-terminal CaM-binding domain in complex 
with CaM, or full length KCa3.1 channels were rendered using the 
UCSF Chimera software (Resource for Biocomputing, Visualization, 
and Informatics, San Francisco, CA).
Potential druggable sites in the Rosetta refined KCa3.1 open 
state-1 structure were identified using the SiteMap function in 
Glide (Schrödinger, LLC, New York, NY, 2018). SiteMap uses a 
site localization method based on interaction energies between 
the protein and grid probes, which is analogous to the Goodford’s 
GRID algorithm. Sites were kept if they comprised at least 50 site 
points. A restrictive hydrophobicity definition and a standard 
grid (1.0 Å) were used for identifying potential binding pockets.
Protein Data Bank (pdb) format files of the Rosetta models of 
KCa3.1 open state 1 and open state 2 with SKA-111 docked in the 
interface between S45A helix and the CaM N-lobe are provided in 
the Data Supplement1; pdb files of all other models are available 
upon request.
Molecular Biology
The cloning of human KCa3.1 (#AF033021) has been reported in the 
late 1990s (Logsdon et al., 1997). The gene was subcloned in-frame 
downstream to green fluorescent protein in the pEGFP-C1 
expression vector (CLONTECH) (Wulff et al., 2001). All clones 
were verified by sequencing. Mutations were introduced using 
QuikChange site directed mutagenesis kit (Stratagene, La Jolla, 
CA) and were verified by fluorescence sequencing. For amino 
acid numbering for KCa3.1 we used the gene: Homo sapiens 
potassium channel, calcium activated intermediate/small 
conductance subfamily N alpha, member 4 (KCNN4). NCBI 
Reference Sequence: NP_002241.1.
Electrophysiology
All experiments were performed in either the inside-out or the whole-
cell configuration of the patch-clamp technique on either transiently 
transfected CHO cells or Human Embryonic Kidney (HEK) cell 
lines stably expressing hKCa3.1 or hKCa2.2 (Sankaranarayanan et al., 
2009). All cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal calf serum. Wild-type (WT) and 
mutant hKCa3.1 channel constructs were transfected using FuGENE 
1 https://frontiersin.figshare.com/collections/The_Trials_and_Tribulations_of_
Structure_Assisted_Design_of_KCa_channel_Activators/4641455
6 transfection reagent (Promega, Madison, WI) in OptiMEM 
reduced-serum medium (Life Technologies, Benicia, CA) for manual 
patch-clamp experiments or via electroporation (Nucleofector 2b 
and Lonza Amaxa Cell Line Nucleofector Kit T) according to the 
manufacturer’s instructions for automated electrophysiology.
Cells transfected using FuGENE 6 were cultured in six-well 
plates for 24–48 h and then detached by TrypLE Express (Gibco, 
Grand Island, NY) and plated on coverslips for 30  min to 1  h 
for whole-cell recordings. For inside-out recordings, cells were 
plated 2–3 h before the experiments to attach them more firmly. 
Coverslips were placed in a 15  ml recording chamber mounted 
on an inverted microscope (Olympus XI-70 equipped with a 
pE-300Lite LED UV light source and filters; Olympus, Tokyo, 
Japan), and only clearly green fluorescent cells were patch-clamped. 
CHO cells transfected via electroporation were cultured in T75 
flasks until 70% confluency and lifted with TrypLE, spun down, 
and resuspended. 1X106 cells were used per transfection with 1 µg 
of plasmid DNA. The setting for the Nucleofector 2b was, cell type: 
CHO, high efficiency. Cells were afterwards cultured in a T25 flask 
for 24 h before they were lifted for electrophysiology.
For manual whole-cell experiments, the extracellular solution 
contained 160 mM NaCl, 4.5 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, and 10 mM HEPES (pH 7.4, 300 mOsm). Solutions on 
the intracellular side contained 154 mM KCl, 10 mM HEPES, 10 
mM EGTA, 1.75 mM MgCl2, and 5.9 mM CaCl2 for a calculated 
free Ca2+ concentration of 250 nM (pH 7.2, 290 mOsm). For inside-
out experiments in symmetrical K+, the extracellular solution 
contained 154 mM KCl, 10 mM HEPES, 1 mM MgCl2, and 2 mM 
CaCl2 (pH 7.4, 300 mOsm). Intracellular solutions contained 154 
mM KCl, 10 mM HEPES, 10 mM EGTA, 1.75 mM MgCl2, and 
varying amounts of CaCl2 for calculated free Ca2+ concentrations 
of 0.05, 0.1, 0.25, 0.5, 1, 10, and 30 mM (pH 7.2, 280–300 mOsm). 
Free Ca2+ concentrations were calculated using the July 3, 2009 
online version of MaxChelator (https://somapp.ucdmc.ucdavis.
edu/pharmacology/bers/maxchelator/webmaxc/webmaxcS.htm) 
assuming a temperature of 25°C, a pH of 7.2, and an ionic strength 
of 160 mM. Patch pipettes were pulled from soda lime glass (micro-
hematocrit tubes; Kimble Chase, Rochester, NY) and had resistances 
of 1.5–3 MΩ when submerged. Experiments were controlled with 
a HEKA EPC-10 amplifier and Patchmaster software (HEKA, 
Lambrecht/Pfalz, Germany). In whole-cell experiments, cells were 
clamped to a holding potential of -80 mV, and KCa currents were 
elicited by 200-ms voltage ramps from -120 to +40 mV applied every 
10 s. For the inside-out experiments, cells were clamped to a holding 
potential of -80 mV, macro-patches were pulled and KCa currents 
were elicited by 200-ms voltage ramps from -80 to +80 mV applied 
every 5 s. Solutions with different free Ca2+ concentrations were 
then perfused in rapid successions to avoid run down. Each Ca2+ 
concentration was normalized to 10 µM of free Ca2+ by perfusing 10 
µM Ca2+ before and after each Ca2+ concentration. If the two 10 µM 
values differed more than 10% from each other, the data point was 
excluded from the Ca2+ concentration response curve.
The procedure for performing automated whole-cell KCa 
channel recordings on a QPatch-16 automated electrophysiology 
platform (Sophion Biosciences) was previously described in detail 
by our laboratory (Jenkins et al., 2013). For the current study we 
used the solutions described above with disposable 16-channel 
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planar patch chip plates (QPlates; patch hole diameter 1  mm, 
resistance 2.00–0.02MΩ, Sophion Biosciences, Woburn, MA). 
Cell positioning and sealing parameters were set as follows: 
positioning pressure -70 mbar, resistance increase for success 
750%, minimum seal resistance 0.1 GΩ, holding potential -0 mV, 
holding pressure -20 mbar. To avoid rejection of cells with large 
KCa3.1 currents, the minimum seal resistance for whole-cell 
requirement was lowered to 0.001 GΩ. Access was obtained with 
the following sequence: 1) suction pulses in 29 mbar increments 
from -250 mbar to -453 mbar; 2) a suction ramp of an amplitude 
of -450 mbar; 3) -400 mV voltage zaps of 1 ms duration. Following 
establishment of the whole-cell configuration, cells were held at 
-80 mV and KCa currents elicited by a voltage protocol that held 
at -80 mV for 20 ms, stepped to -120 mV for 20 ms, ramped from 
-120 to + 40 mV in 200 ms, and then stepped back to -120 mV for 
20 ms. This pulse protocol was applied every 10 s. KCa activator 
dilutions were prepared freshly (within 5 min of the initiation of 
the QPatch) with Ringer’s solution from 10 mM stock solutions 
in dry DMSO. Final DMSO concentrations never exceeded 1%. 
Glass vial inserts (to avoid adsorption) were filled with 400 
µL of compound solution and placed into the insert base plate 
for use in the QPatch assay. Exemplary QPatch raw current 
traces and plots of slope conductance versus time are shown 
in Supplementary Figure 3. For each compound we typically 
used 12 consecutive liquid periods Break-in, 3 saline additions to 
stabilize the current, 2 additions of test compound at 10 µM, 2 
saline washes, 2 additions of SKA-31 at 10 µM, followed by 2 more 
saline washes. In each liquid period 10 pulse protocols were run.
Data analysis, fitting, and plotting were performed with 
IGOR-Pro (Wavemetrics, Lake Oswego, OR) or Origin 9 (OriginLab 
Corporation, Northampton, MA).
Calcium Sensitivity Testing
When screening mutants, we always first assessed whether 
mutations had altered Ca2+ sensitivity in a two-step process. First, 
mutant channels were patched with an intracellular solution 
containing 10 µM of free Ca2+. If the mutant did not display currents 
with amplitudes in the nA range under these conditions, we then 
tested whether the channel’s control current (at 250 nM free Ca2+) 
could be increased 5–10-fold in the presence of 100 µM EBIO 
(this fold increase level is common in the wild type channel). If the 
mutant did not meet either threshold it was deemed to have altered 
Ca2+ sensitivity and was excluded from subsequent experiments 
investigating sensitivity to SKA-111. All mutants shown in Figure 7 
or mentioned in the text exhibited current densities at +40 mV that 
were comparable to the WT channel and produced currents that 
were large enough to perform experiments. WT: 19.5 ± 23.4 pA/
pF; T212F-V272F: 12.4 ± 10.4 pA/pF; S181A: 11.6 ± 16.2 pA/pF; 
A184F: 7.2 ± 5.4 pA/pF; L185A: 6.9 ± 6.5 pA/pF; S181A-L185A: 
8.8 ± 5.5 pA/pF; S372R: 13.8 ± 12.5 pA/pF (n = 5).
Chemistry
Commercially Available Compounds
4-Biphenyl-4-yl-thiazol-2-ylamine (SKA-232, CAS 2834-
79-9) was purchased from Sigma–Aldrich (St. Louis, MO). 
Bis-4,4’-(2-amino-4-thiazolyl)biphenyl (SKA-255, CAS 438233-
93-3) was purchased from Oakwood Products, INC (West 
Columbia, SC). Identity and purity (<95%) of commercial 
compounds was confirmed by 1H NMR before using compounds 
for electrophysiological testing.
Chemical Synthesis
Compounds that were not commercially available were synthesized 
in our laboratory according to the general methods described 
below. Compounds reported previously were characterized by 
melting point, proton nuclear magnetic resonance (1H NMR) and 
13 carbon (13C) NMR. All NMR spectra were recorded on an 800 
MHz Bruker Avance III spectrometer. Data are reported as follows: 
chemical shift (δ), multiplicity, integration, coupling constant (Hz). 
Signals are designated as follows: s (singlet), d (doublet), dd (doublet 
of doublets), ddd (doublet of doublet of doublets), dt (doublet of 
triplets), t (triplet), quint (quintet), m (multiplet). New chemical 
entities were additionally characterized by high-resolution mass 
spectrometry (HRMS). For compounds (SKA-218, SKA-339, SKA-
340, SKA-343 and SKA-347) where it was difficult to unambiguously 
confirm the structure based on 1H and 13C NMR, we grew crystals 
and subjected them to X-ray analysis, which allowed us to see the 
exact position of the substituents in the compounds. All compounds 
used for electrophysiological experiments were at least 95–98% 
 pure based on NMR and/or mass spectrometry.
General Method I. Preparation of nitro-substituted 
2-metylnaphtho[1,2-d]thiazoles or 1-substituted 
4-nitronaphthalenes
One milliliter of HNO3 was added slowly to 1 g of 2-methyl-β-
naphthothiazole or 1-substituted naphthalene in a round bottom 
flask at room temperature without solvent. The reaction mixture 
was stirred for 1 h and then 1.5 ml of H2SO4 (95%) was added 
slowly. The mixture was stirred at room temperature for 30 min 
until completion of the reaction was indicated by the disappearance 
of starting material on thin-layer chromatography (TLC). Then 
the pH of the reaction mixture was adjusted to between 7 and 
7.5 with 4N NaOH, the mixture extracted with ethyl acetate and 
the organic phase washed with water and brine. The extract was 
dried with anhydrous sodium sulfate and solvent was evaporated 
under reduced pressure. The crude product was purified via flash-
chromatography (petroleum ether: ethyl acetate, 8:2).
General Method II. Preparation of amino-substituted 
2-metylnaphtho[1,2-d]thiazoles or 1-amino 
4-substituted naphthalenes
One gram of the previously prepared nitro-substituted 
2-metylnaphtho[1,2-d]thiazole or 1-substituted 4-nitronaphthalene 
was dissolved in 30 mL of 95% ethanol and 5% water, 20 mg of 
palladium charcoal was added and then 2 mL of hydrazine were 
dropped in slowly. After the addition was completed, the reaction 
mixture was stirred at 80°C for 12 h and the progress of the reaction 
was monitored by TLC with dichloromethane. After completion, the 
reaction mixture was filtered to remove the palladium charcoal and 
concentrated to dryness under vacuum. The residue was dissolved 
in ethyl acetate and was washed with water and brine. The organic 
KCa Channel Activator DesignShim et al.
5 September 2019 | Volume 10 | Article 972Frontiers in Pharmacology | www.frontiersin.org
phase was dried with anhydrous sodium sulfate and the solvent was 
removed under vacuum. The crude product was purified by flash-
chromatography with ethyl acetate/petroleum ether (3:7 v/v) as 
eluent to give the product.
General Method III. Preparation of methyl-substituted 
acetonaphthones
Acetylchloride (750 μl, 10 mmol) and AlCl3 (1.33 g, 10 mmol) 
were added sequentially to 20  ml of chloroform at room 
temperature. Methyl substituted naphthalenes (1 ml, 7 mmol) in 
5 ml of chloroform were then added, the reaction mixture was 
stirred for 2 h, and the progress of the reaction was monitored 
by TLC. The reaction mixture was quenched with sodium 
bicarbonate solution and washed with water and brine. Solvent 
was removed under reduced pressure to give the crude product. 
The crude product was purified by flash–chromatography using 
ethyl acetate/petroleum ether (2:8 v/v).
General Method IV. Preparation of substituted 2-bromo-
1-(methyl substituted naphthalen-1-yl)ethan-1-one or 
2-bromo-1-(methyl substituted cyclohex-1-yl)ethan-1-one
Appropriately substituted acetophenones were dissolved in 
chloroform (20  ml) at room temperature and the reaction 
mixture was stirred. Liquid bromine (1.2–1.5 equivalent) in 
chloroform (5  ml) was then added drop-wise. The progress of 
the reaction was monitored by TLC. The reaction mixture was 
quenched with a saturated aqueous solution of sodium hydrogen 
carbonate and the pH was adjusted to between 7 and 7.5. The 
organic phase was washed with water and brine and the solvent 
was removed under vacuum. The crude residue was purified via 
flash chromatography (petroleum ether: ethyl acetate, 7:3).
General Method V. Preparation of substituted 
4-phenylthiazole or 4-naphthalenyl thiazoles
Substituted 2-bromo-1-(methyl substituted naphthalen-1-yl)
ethan-1-one or 2-bromo-1-(methyl substituted cyclohex-1-yl)
ethan-1-one was added to a solution of a substituted thiourea 
in 20 ml of absolute ethanol. The mixture was refluxed for 2 h. 
After completion of the reaction, the ethanol was evaporated 
under vacuum. The dried reaction mixture was dissolved in 
dichloromethane and neutralized with saturated NaHCO3. The 
organic phase was washed with water and brine, and then dried 
with anhydrous Na2SO4. Finally, the solvent was evaporated under 
vacuum. The crude product was reconstituted in a methanol, 
treated with charcoal and recrystallized.
General Method VI. Preparation of heterocyclic 
1-substituted 4-nitronaphthalenes
1-Fluoro-4-nitronaphthalene and a secondary or heterocyclic 
amine (molar ratio 1:3) were dissolved in 10 mL of DMF at 90°C. 
Potassium carbonate (3 equivalents) was then added. The reaction 
mixture was stirred and monitored by TLC. After completion, the 
reaction mixture was washed with brine several times to remove 
the DMF and extracted with ethyl acetate. Solvent was evaporated 
to give the crude product. The crude product was purified by flash-
chromatography using ethyl acetate/petroleum ether (2:8 v/v).
General Method VII. Preparation of substituted 
2-aminonaphthothiazoles
Liquid bromine (150 μL, 3 mmol) and KSCN (485 mg, 5 
mmol) were added to a solution of the 1-amino 4-substituted 
naphthalenes (3 mmol) in 10 ml of acetic acid and the reaction 
mixture was stirred at room temperature for 30 min. The reaction 
was quenched by adding 4N NaOH. The reaction mixture was 
then washed with water and brine and extracted with ethyl 
acetate. Solvent was evaporated to give the crude product, 
which was purified by flash-chromatography using ethyl acetate/
petroleum ether (3:7 v/v).
General Method VIII. Preparation of N-substituted 
naphtho[1,2-d]thiazol-2-amine
1-Naphthylamine 500 mg (3.5 mmol) was dissolved in 25 mL 
chloroform and 0.3 mL of trimethylamine before adding 
substituted isothiocyanate (3.8 mmol). The resulting mixture 
was refluxed at 65°C for 48  h. Solvent was then evaporated, 
and the resulting solid was washed with diethyl ether to obtain 
N,N’-disubstituted thiourea. The N,N’-disubstituted thiourea 
(2.2 mmol) obtained in the previous step was suspended in 25 
mL chloroform, and a solution of liquid bromine in chloroform 
(1 eq.) added over a period of 1 h, after which sodium thiosulfate 
(aq.) was added to the reaction mixture. The reaction mixture 
was washed with 4N NaOH (aq.) and the organic layer was 
dried over anhydrous sodium sulfate and evaporated under 
reduced pressure.
2-Methylnaphtho[1,2-d]thiazole-5-carbonitrile (SKA-126). To 
a solution of 5-bromo-2-methylnaphtho[1,2-d]thiazole (SKA-132, 
280 mg, 1 mmol) in a mixture of DMF (3 mL) and water (200 uL), 
kept under nitrogen, were added copper (I) cyanide (CuCN, 121 mg, 
1.33 mmol), Pd2(dba)3 (Tris (dibenzylideneacetone) dipalladium 
(0), 70 mg) and 1,1′-ferrocenediyl-bis(diphenylphosphine) (dppf, 
80 mg). The resulting solution was heated at 110°C for 75 h, after 
which the mixture was filtered and diluted with 10 mL water and 
was extracted using chloroform (3X10 mL). The organic layer was 
separated, dried over anhydrous sodium sulfate and evaporated 
under reduced pressure. Chromatographic purification of the 
crude product on silica gel using ethyl acetate and hexane (10:90) 
furnished 120 mg (50%) of the required product as off white solid 
and 85 mg starting material: m.p = 139–140°C. 1H NMR (800 MHz, 
CDCl3): δ = 8.85–8.82 (m, 1H), 8.34–8.31 (m, 2H), 7.80–7.74 (m, 
2H), 2.99 (s, 3H). 13C NMR (201 MHz, CDCl3): δ = 170.8, 152.7, 
130.7, 130.6, 128.5, 128.30, 128.0, 126.5, 125.6, 124.7, 117.9, 107.3, 
20.6. HRMS (ESI): m/z calculated for C13H8N2S (M+H)+: 225.0485 
found: 225.0485.
2-Aminonaphtho[1,2-d]oxazole-5-sulfonic acid (SKA-128). 
To a solution of 4-amino-3-hydroxynaphthalene-1-sulfonic 
acid (1.0 g, 4.18 mmol) and 3.0 mL Hunig’s base in 50 mL (9:1) 
ethanol:water was added 850 mg of cyanogen bromide. The 
resulting mix was stirred at room temperature for 4  d. After 
completion of the reaction the solvent was evaporated, and the 
residue was dissolved in water. It was acidified by adding 1N HCl. 
The precipitate thus obtained was filtered, washed with acetone, 
and dried to render 800 mg (81%) of pink-brown solid: m.p = 
295°C (Decomposes).1H NMR (800 MHz, DMSO-d6 & Et3N): δ 
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= 8.92 (dt, J = 8.6, 0.9 Hz, 1H), 8.20 – 8.16 (m, 1H), 8.07 (s, 1H), 
7.63 (s, 2H), 7.56 (ddd, J = 8.1, 6.7, 1.2 Hz, 1H), 7.50 (ddd, J = 
8.3, 6.7, 1.5 Hz, 1H). 13C NMR (201 MHz, DMSO-d6 & Et3N): δ = 
163.6, 141.8, 139.3, 136.9, 128.3, 126.8, 125.3, 124.2, 124.1, 121.5, 
108.9. HRMS (ESI): m/z calculated for C11H8N2O4S (M+H)+: 
265.0278 found: 265.0284.
5-Chloro-2-methylnaphtho[1,2-d]thiazole (SKA-130). 2- 
Methyl-β-naphthothiazole (400 mg, 2 mmol), N-chlorosuccinamide 
(266 mg, 2 mmol), NaCl (117 mg, 2 mmol) and P-TSOH (344 mg, 2 
mmol) were dissolved in 30 ml of acetonitrile. The reaction mixture 
was stirred at 40°C for 2  h, and the progress of the reaction was 
monitored by TLC using an ethyl acetate:petroleum ether mixture 
(3:7). After completion, the reaction mixture was filtered and 
washed with water and acetonitrile. The residue was recrystallized 
from methanol as light yellow crystals (100 mg, 21%); m.p. = 103°C. 
1H NMR (800 MHz, CDCl3): δ = 8.81 (dd, J = 8.2, 1.3 Hz, 1H), 8.37 
(d, J = 8.3 Hz, 1H), 7.99 (s, 1H), 7.74 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 
7.70 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 2.96 (s, 3H). 13C NMR (201 MHz, 
CDCl3),: δ = 166.3, 148.6, 131.3, 129.0, 129.0, 128.7, 127.6, 126.8, 
124.9, 124.2, 118.9, 20.1. HRMS (ESI): m/z calculated for C12H8ClNS 
(M+H)+: 243.0138; found: 243.0135.
5-Bromo-2-methylnaphtho[1,2-d]thiazole (SKA-132). To a 
solution of 2-methylnaphtho[1,2-d]thiazole (1.0  g, 5 mmol) in 
25 mL chloroform was added a solution of molecular bromine 
in chloroform (I eq) over a period of 2  min and the resulting 
solution was stirred for 30  min at room temperature after 
which sodium thiosulfate (aq.) was added. This was followed 
by washing with 4N NaOH (aq.). The organic layer was dried 
over anhydrous sodium sulfate and evaporated under reduced 
pressure to obtain 1202 mg (85%) The product was isolated as 
white solid; m.p = 98–99°C (CAS 125427-01-2).1H NMR (800 
MHz, CDCl3): δ = 8.78 (dd, J = 8.1, 1.4 Hz, 1H), 8.33–8.30 (m, 
1H), 8.16 (s, 1H), 7.70 (ddd, J = 8.1, 6.8, 1.3 Hz, 1H), 7.67 (ddd, 
J = 8.3, 6.9, 1.4  Hz, 1H), 2.93 (s, 3H). 13C NMR (201 MHz, 
CDCl3): δ = 166.5, 149.4, 132.0, 130.2, 129.0, 127.8, 127.7, 
127.2, 124.4, 122.6, 119.6, 20.3.
5-Bromo-2-methylnaphtho[1,2-d]oxazole (SKA-133). SKA-133 
was prepared from 2-methylnaphtho[1,2-d]oxazole (1.0 g, 5.45 
mmol) following the method described above for the synthesis 
of SKA-132. The product was isolated as a white solid (90%); m.p 
= 101–102°C (CAS 1838658-03-9). 1H NMR (800 MHz, CDCl3): 
δ = 8.45 (dd, J = 8.2, 1.3 Hz, 1H), 8.33 (dd, J = 8.5, 1.1 Hz, 1H), 
7.99 (s, 1H), 7.68 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.63 (ddd, J = 8.3, 
6.9, 1.3 Hz, 1H), 2.73 (s, 3H). 13C NMR (201 MHz, CDCl3): δ = 
163.4, 147.6, 136.7, 129.3, 128.1, 127.8, 126.7, 126.6, 122.5, 118.9, 
115.1, 14.8.
Naphtho[2,3-d]oxazol-2-amine (SKA-134). SKA-134 was 
prepared from 3-aminonaphthalen-2-ol and cyanogen bromide 
following the method described for the synthesis of SKA-128. 
The product was isolated as a white solid (97%); m.p = 247–
248°C (CAS 1820618-76-5). 1H NMR (800 MHz, DMSO-d6): 
δ = 7.93–7.87 (m, 2H), 7.80 (d, J = 0.8 Hz, 2H), 7.76 (s, 3H), 
7.61 (d, J = 0.9 Hz, 2H), 7.39 (dddd, J = 26.3, 8.3, 6.8, 1.5 Hz, 1H). 
13C NMR (201 MHz, DMSO-d6): δ = 164.3, 148.5, 144.3, 131.6, 
129.1, 127.9, 127.5, 124.5, 123.7, 110.8, 104.3.
2-Methylnaphtho[1,2-d]oxazole-5-carbonitrile (SKA-135). 
SKA-135 was prepared from 5-bromo-2-methylnaphtho[1,2-d]
oxazole (SKA-133) and CuCN following the method described 
for the synthesis of SKA-126. The product was isolated as a 
brownish crystal (42%); m.p. = 145–146°C (CAS 60111-00-4). 1H 
NMR (800 MHz, CDCl3): δ = 8.50–8.46 (m, 1H), 8.31 (dt, J = 8.2, 
0.9 Hz, 1H), 8.05 (s, 1H), 7.74 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.71 
(ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 2.78 (s, 3H). 13C NMR (201 MHz, 
CDCl3): δ = 166.4, 146.2, 141.3, 130.5, 128.5, 127.8, 126.0, 125.9, 
122.8, 117.9, 117.3, 106.4, 14.9.
N-Phenylnaphtho[1,2-d]thiazol-2-amine (SKA-146). SKA-146 
was prepared from 1-naphthylamine and phenylisothiocyanate 
according to General Method VIII. The product was isolated as 
a white solid (320 mg, 42%); m.p = 140–141°C (CAS 21431-44-
7). 1H NMR (800 MHz, DMSO-d6): δ = 10.67 (s, 1H), 8.58 (dt, J 
= 8.1, 1.0 Hz, 1H), 8.02 (dd, J = 8.1, 1.1 Hz, 1H), 7.99 – 7.94 (m, 
3H), 7.75 (d, J = 8.5 Hz, 1H), 7.67 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 
7.58 (ddd, J = 8.1, 6.8, 1.3 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.09 (tt, 
J = 7.3, 1.1 Hz, 1H). 13C NMR (201 MHz, DMSO-d6): δ = 162.3, 
147.3, 140.8, 131.7, 129.1, 128.0, 126.2, 126.1, 125.4, 124.7, 123.4, 
122.2, 121.9, 119.1, 117.5.
N-Methylnaphtho[1,2-d]thiazol-2-amine (SKA-158). SKA-158 
was prepared from1-naphthylamine and methylisothiocyanate 
according to General Method VIII. The product was isolated as a 
white solid (42%); m.p = 187–188°C (CAS 876484-23-0).1H NMR 
(800 MHz, DMSO-d6): δ = 8.45 (dd, J = 8.2, 1.2 Hz, 1H), 8.13 (d, 
J = 4.8 Hz, 1H), 7.97 – 7.84 (m, 2H), 7.60 (d, J = 8.5 Hz, 1H), 7.57 
(ddd, J = 8.2, 6.7, 1.3 Hz, 1H), 7.51 (ddd, J = 8.1, 6.7, 1.3 Hz, 1H), 
3.07 (d, J = 4.5 Hz, 3H). 13C NMR (201 MHz, DMSO-d6): δ = 
168.1, 147.9, 131.6, 127.9, 125.8, 125.5, 125.1, 124.3, 123.5, 120.5, 
119.3, 30.7.
N-Cyclohexylnaphtho[1,2-d]thiazol-2-amine (SKA-165). 1-Naphthyl 
isothiocyanate (2 g, 10.8 mmol) was added to 20 mL of ethanol 
and the mixture was stirred and refluxed at 80°C. Then, 1.24 
mL (10.8 mmol) of cyclohyxylaminenaphtho[1,2-d]thiazol-2-
ylamine was added and the mixture refluxed for 2 h. The progress 
of the reaction was monitored by TLC. After completion of 
the reaction ethanol was removed under vacuum, the residue 
extracted with ethyl acetate and the organic phase washed 
with water followed by brine. The organic layer was dried with 
anhydrous Na2SO4 and the solvent was evaporated. 700 mg (2.46 
mmol) of the intermediate product, 1-cyclohexyl-3-(naphthalen-
1-yl)thiourea, was dissolved in 20 mL of chloroform. Then 131.1 
uL (2.46 mmol) of liquid bromine was added dropwise. After 
completion the reaction was quenched by adding 4N NaOH, 
the resulting mixture was washed with water and brine and 
extracted with ethyl acetate. Finally, the solvent was evaporated 
under vacuum. The crude product was reconstituted in a 
methanol, treated with charcoal and recrystallized. The product 
was isolated as a brownish crystal. (460 mg, 17%); m.p = 115–
116°C (CAS 1368045-48-0).1H NMR (800 MHz, DMSO-d6): 
δ = 8.38 (d, J = 8.2 Hz, 1H), 8.10 (d, J = 7.4 Hz, 1H), 7.89 (d, 
J = 8.0 Hz, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.56 - 7.50 (m, 2H), 
7.46 (t, J = 7.4 Hz, 1H), 3.74 (s, 1H), 2.12 - 1.96 (m, 2H), 1.76 
(dt, J = 13.1, 4.0  Hz, 2H), 1.61 (dt, J = 13.3, 4.0  Hz, 1H), 1.36 
(dddd, J = 37.2, 15.2, 12.0, 5.8 Hz, 4H), 1.22 (dtd, J = 15.5, 11.8, 
9.5, 6.0 Hz, 1H).13CNMR(201MHz, DMSO-d6): δ = 166.8, 148.3, 
132.1, 128.3, 125.9, 125.52, 124.5, 123.9, 120.9, 119.7, 79.6, 53.7, 
32.7, 25.7, 24.9.
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2-Methylnaphtho[1,2-d]thiazol-6-amine (SKA-172). SKA-
172 was prepared from 2-methyl-6-nitronaphtho[1,2-d]thiazole 
(SKA-215) in 2 steps according to General methods I and II. The 
resulting residue was purified by flash-chromatography with 
ethyl acetate/petroleum ether (3:7 v/v) as eluent to give SKA-172 
as reddish crystals (40 mg, 19%); m.p. = 148–150°C. 1H NMR (800 
MHz, CDCl3): δ = 8.08 (dd, J = 8.9, 0.8 Hz, 1H), 7.94 (d, J = 8.9 Hz, 
1H), 7.87 (dt, J = 8.1, 1.0 Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 6.81 (dd, 
J = 7.6, 1.1 Hz, 1H), 5.89 (s, 2H), 2.91 (s, 3H). 13C NMR (201 MHz, 
DMSO-d6): δ = 165.7, 149.4, 145.8, 131.7, 129.4, 128.2, 120.8, 
120.3, 117.1, 111.1, 108.7, 20.2. HRMS (ESI): m/z calculated for 
C12H10N2S (M+H)+: 215.0637; found: 215.0635.
2-Methylnaphtho[1,2-d]thiazol-9-amine (SKA-178). SKA-
178 was prepared from 2-methyl-9-nitronaphtho[1,2-d]thiazole 
(SKA-216) in 2 steps according to General methods I and II as 
green crystals (39 mg, 17%); m.p = 87-88°C. 1H NMR (800 MHz, 
CDCl3): δ = 8.01 (d, J = 8.7 Hz, 1H), 7.76 (d, J = 8.7 Hz, 1H), 
7.34 (t, J = 7.7 Hz, 1H), 7.22–7.19 (m, 1H), 7.11 (s, 2H), 6.86 
(dd, J = 7.6, 1.1  Hz, 1H), 2.97 (s, 3H). 13C NMR (201 MHz, 
DMSO-d6): δ = 164.9, 148.6, 145.7, 134.1, 130.7, 127.4, 126.4, 
119.5, 115.4, 115.1, 109.5, 20.2. HRMS (ESI): m/z calculated for 
C12H10N2S (M+H)+: 215.0637; found: 215.0635.
4-(4-Methylnaphthalen-1-yl)thiazol-2-amine (SKA-190). 
SKA-190 was prepared from 1-methylnaphthalene in 3 steps 
according to General methods III, IV, and V. The product was 
obtained as golden crystals (355 mg, 21%); m.p = 168–169°C 
(CAS 332064-25-2). 1H NMR (800 MHz, DMSO-d6): δ = 8.49 
(dd, J = 8.4, 1.3 Hz, 1H), 8.09–8.06 (m, 1H), 7.60 (ddd, J = 8.3, 
6.7, 1.4 Hz, 1H), 7.57–7.53 (m, 2H), 7.40 (dd, J = 7.2, 1.1 Hz, 1H), 
7.12 (s, 2H), 6.74 (s, 1H), 2.70 (d, J = 1.0 Hz, 3H). 13C NMR (201 
MHz, DMSO-d6): δ = 168.6, 150.3, 135.5, 132.9, 131.9, 131.8, 
128.9, 128.4, 127.6, 126.8, 124.5, 124.3, 102.3, 21.7.
4-(7-Methylnaphthalen-1-yl)thiazol-2-amine (SKA-193). 
SKA-193 was prepared from 2-methylnaphthalene in 3 steps 
according to General methods III, IV, and V. The product was 
isolated as light yellow powder (70 mg, 4%); m.p. = 154–156°C. 
1H NMR (800 MHz, CDCl3): δ = 8.06 (d, J = 1.8 Hz, 1H), 7.82 
(d, J = 8.2 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.60 (dd, J = 7.0, 
1.2 Hz, 1H), 7.43 (dd, J = 8.1, 7.0 Hz, 1H), 7.35 (dd, J = 8.3, 
1.6 Hz, 1H), 6.64 (s, 1H), 5.41 (d, J = 150.2 Hz, 2H), 2.52 (s, 3H). 
13C NMR (201 MHz, DMSO-d6): δ = 168.3, 150.6, 135.4, 133.3, 
132.2, 131.4, 128.4, 128.3, 128.1, 127.2, 125.4, 124.9, 105.2, 22.2. 
HRMS (ESI): m/z calculated for C14H12N2S (M+H)+: 241.0794; 
found: 241.0793.
4-(6-Methylnaphthalen-2-yl)thiazol-2-amine (SKA-198). 
SKA-198 was prepared from 2-methylnaphthalene in 3 steps 
according to General methods III, IV, and V. The product was 
isolated as light yellow powder (110 mg, 7%); m.p. = 178–179°C. 
1H NMR (800 MHz, DMSO-d6): δ = 8.31–8.28 (m, 1H), 7.94 
(dd, J = 8.6, 1.7  Hz, 1H), 7.83 (dd, J = 24.8, 8.5  Hz, 2H), 7.69 
(s, 1H), 7.38 (dd, J = 8.4, 1.7 Hz, 1H), 7.15 (d, J = 14.1 Hz, 3H), 
2.55 (s, 3H). 13C NMR (201 MHz, DMSO-d6): δ = 168.6, 150.3, 
135.5, 132.9, 131.9, 131.8, 128.9, 128.4, 127.6, 126.8, 124.5, 124.3, 
102.3, 21.7. HRMS (ESI): m/z calculated for C14H12N2S (M+H)+: 
241.0794; found: 241.0792.
N,5-Dimethylnaphtho[1,2-d]thiazol-2-amine (SKA-204). 
SKA-204 was prepared from 2-Methyl-1-naphthylamine and 
methylisothiocyanate according to General Method VIII. The 
product was isolated as a white solid (35%). m.p = 172–173°C 
(CAS 1369251-74-0). 1H NMR (800 MHz, DMSO-d6): δ = 8.50–
8.48 (m, 1H), 8.04–8.00 (m, 2H), 7.70 (d, J = 1.2 Hz, 1H), 7.58 
(dddd, J = 20.1, 8.2, 6.7, 1.4 Hz, 2H), 3.05 (d, J = 4.7 Hz, 3H), 2.67 
(s, 3H). 13C NMR (201 MHz, DMSO-d6): δ = 167.3, 146.7, 130.6, 
126.5, 126.0, 125.3, 125.0, 124.4, 124.0, 123.98, 119.3, 30.7, 19.0.
2-Methyl-6-nitronaphtho[1,2-d]thiazole (SKA-215). SKA-215 
was prepared from 1 g of 2-methyl-β-naphthothiazole according 
to General Method I. The product was isolated as light-yellow 
powder (200 mg, 6%); m.p. = 178–179°C. 1H NMR (800 MHz, 
DMSO-d6): δ = 9.15 (dt, J = 8.2, 1.1 Hz, 1H), 8.49 (dd, J = 9.2, 
0.8 Hz, 1H), 8.29 (dd, J = 7.6, 1.3 Hz, 1H), 8.09 (d, J = 9.2 Hz, 1H), 
7.74 (t, J = 7.9 Hz, 1H), 2.99 (s, 3H). 13C NMR (201 MHz, CDCl3): 
δ = 167.6, 149.3, 147.0, 133.1, 130.2, 129.3, 125.2, 123.5, 123.5, 
122.4, 119.6, 20.2. HRMS (ESI): m/z calculated for C12H8N2O2S 
(M+H)+: 245.0379; found: 245.0376.
2-Methyl-9-nitronaphtho[1,2-d]thiazole (SKA-216). SKA-216 
was prepared from 1 g of 2-methyl-β-naphthothiazole according 
to General Method I. The product was isolated as light-yellow 
crystals (280 mg, 22%); m.p. = 151–152°C. 1H NMR (800 MHz, 
DMSO-d6): δ = 8.10 (d, J = 8.0  Hz, 1H), 8.01 (d, J = 8.7  Hz, 
1H), 7.85 (d, J = 8.7 Hz, 1H), 7.72 (d, J = 7.4 Hz, 1H), 7.60 (t, 
J = 7.8 Hz, 1H), 2.92 (s, 3H). 13C NMR (201 MHz, DMSO-d6): 
δ = 167.6, 146.9, 144.3, 135.4, 133.0, 131.9, 125.8, 125.6, 122.2, 
121.6, 117.2, 20.4. HRMS (ESI): m/z calculated for C12H8N2O2S 
(M+H)+: 245.0379; found: 245.0376.
5,6-Dinitronaphtho[1,2-d]thiazol-2-amine (SKA-218). 
SKA-218 was prepared from 1  g of 2-methyl-β-naphthothiazole 
according to General Method I. The product was isolated as light 
brownish crystals (210 mg, 13.3%): m.p. = 172°C. 1H NMR (800 
MHz, DMSO-d6): δ = 9.31 (s, 1H), 9.15 (dd, J = 8.2, 1.2 Hz, 1H), 
8.50 (dd, J = 7.6, 1.2 Hz, 1H), 8.04 (dd, J = 8.2, 7.6 Hz, 1H), 3.02 (s, 
3H). 13C NMR (201 MHz, DMSO-d6): δ = 175.7, 152.1, 145.9, 141.5, 
131.8, 130.4, 128.8, 128.6, 126.9, 123.8, 114.7, 20.8. HRMS (ESI): 
m/z calculated for C12H7N3O4S (M+H)+: 290.02; found: 290.02.
5-Bromo-4-(naphthalen-2-yl)thiazol-2-amine (SKA-220). 
2-Amino-4-(2-naphthy)thiazole (106 mg, 0.46 mmol) was 
dissolved in 10  ml of chloroform. Liquid bromine (30 μl, 0.46 
mmol) in chloroform (3  ml) was then added drop-wise. The 
reaction mixture was stirred at room temperature for 30  min. 
The progress of the reaction was monitored by TLC. The reaction 
mixture was quenched with 4N NaOH and washed with sodium 
thiosulfate, water and brine. The organic phase was dried with 
anhydrous sodium sulfate and the solvent was evaporated under 
vacuum. The crude product was recrystallized from methanol. 
The product was isolated as light brown crystals (100 mg, 40%); 
m.p. = 140–141°C (CAS 99514-91-7). 1H NMR (800 MHz, 
DMSO-d6): δ = 8.35 (s, 1H), 7.96 (s, 2H), 7.99–7.91 (m, 2H), 
7.56–7.52 (m, 2H), 7.38 (s, 2H). 13C NMR (201 MHz, DMSO-d6): 
δ = 167.4, 147.5, 133.0, 132.7, 131.7, 128.6, 128.0, 127.9, 127.5, 
126.96, 126.9, 126.1, 88.0.
4,4'-(1,4-Phenylene)bis(thiazol-2-amine) (SKA-230). SKA-
230 was prepared from 1,4-acetylbenzene in 2 steps according 
to general method IV, V. The product was isolated as light-
yellow powder (197 mg, 47%); m.p. = 350°C (CAS 13355-22-1). 
1H NMR (800 MHz, DMSO-d6): δ = 8.59 (s, 4H), 7.89 (s, 4H), 
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7.35 (s, 2H). 13C NMR (201 MHz, DMSO-d6): δ = 170.3, 128.0, 
126.6, 119.9, 103.9.
4-(Naphthalen-1-yl)-N-(3-(trif luoromethyl)phenyl)
thiazol-2-amine (SKA-251). SKA-251 was prepared from 
1-acetonaphthone (500 mg, 2.94 mmol) and 3-(trifluoromethyl)
phenylthiourea in 2 steps according to General methods IV 
and V. The product was isolated as white crystals (50 mg, 
4.6%); m.p. = 135°C. 1H NMR (800 MHz, DMSO-d6): δ = 10.73 
(s, 1H), 8.55 (d, J = 8.5 Hz, 1H), 8.38 (d, J = 2.1 Hz, 1H), 8.01 
(m, 2H), 7.77 (ddd, J = 16.4, 7.6, 1.7 Hz, 2H), 7.56 (m, 4H), 
7.27 (m, 2H). 13C NMR (201 MHz, DMSO-d6): δ = 162.7, 
150.7, 142.2, 134.0, 133.1, 131.1, 130.5, 128.9, 128.7, 127.4, 
126.6, 126.4, 126.2, 125.9, 120.7, 117.7, 117.6, 113.0, 113.0, 
108.0. HRMS (ESI): m/z calculated for C20H13F3N2S(M+H)+: 
371.0825; found: 371.0832.
4-(Naphthalen-1-yl)-N-(pyridin-2-yl)thiazol-2-amine (SKA-
258). SKA-258 was prepared from 1-acetonaphthone and 
2-pyridylthiourea in 2 steps according to General methods IV 
and V. The product was isolated as white powder (436 mg, 
35%); m.p. = 225°C. 1H NMR (800 MHz, DMSO-d6): δ = 11.51 
(s, 1H), 8.53 (m, 1H), 8.39 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 7.99 
(m, 1H), 7.96 (m, 1H), 7.75 (m, 2H), 7.59 (m, 3H), 7.26 (s, 1H), 
7.15 (dt, J = 8.3, 1.0 Hz, 1H), 6.99 (ddd, J = 7.2, 5.0, 1.0 Hz, 
1H).13C NMR (201 MHz, DMSO-d6): δ = 159.6, 152.3, 149.2, 
147.0, 138.3, 134.0, 133.7, 131.1, 128.6, 128.5, 127.3, 126.5, 126.5, 
126.3, 125.9, 116.4, 111.2, 110.1. HRMS (ESI): m/z calculated for 
C18H13N3S (M+H)+: 304.0903; found: 304.0905.
4-(p-Tolyl)-N-(3-(trif luoromethyl)phenyl)thiazol-2-
amine (SKA-260). SKA-260 was prepared from 2-bromo-4’-
methylacetophenone (500 mg, 2.34 mmol) and 3-(trifluoromethyl)
phenylthiourea according to General Method V. The product was 
isolated as orange crystals (744 mg, 95%); m.p. = 108°C (CAS 
778566-59-9). 1H NMR (800 MHz, DMSO-d6): δ = 10.68 (s, 1H), 
8.42 (t, J = 2.0 Hz, 1H), 7.89 (dd, J = 8.2, 2.2 Hz, 1H), 7.85 (m, 2H), 
7.61 (t, J = 7.9 Hz, 1H), 7.39 (s, 1H), 7.33 (m, 1H), 7.29 (m, 2H), 
2.37 (s, 3H). 13C NMR (201 MHz, DMSO-d6): δ = 162.9, 150.5, 
142.2, 137.5, 132.1, 130.6, 130.2, 130.1, 129.7, 125.9, 125.4, 124.1, 
120.6, 117.6, 113.1, 103.3, 21.2.
4-Phenyl-N-(pyridin-2-yl)thiazol-2-amine (SKA-265). 
SKA-265 was prepared from 2-bromoacetophenone (500 
mg, 2.5 mmol) and 2-pyridylthiourea according to General 
Method V. The product was isolated as white crystals (495 mg, 
78%); m.p. = 158°C (CAS 92663-22-4). 1H NMR (800 MHz, 
DMSO-d6),: δ = 11.41 (s, 1H), 8.32 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 
7.92 (m, 2H), 7.72 (ddd, J = 8.4, 7.1, 1.9 Hz, 1H), 7.43 (m, 3H), 
7.31 (td, J = 7.3, 1.3 Hz, 1H), 7.11 (dd, J = 8.3, 1.0 Hz, 1H), 6.94 
(ddd, J = 7.2, 5.0, 1.0 Hz, 1H). 13C NMR (201 MHz, DMSO-d6): 
δ = 159.9, 152.3, 149.0, 146.9, 138.3, 135.2, 129.0, 127.9, 126.0, 
116.4, 111.2, 106.3, 40.3, 39.7.
4-Phenyl-N-(4-(trifluoromethyl)phenyl)thiazol- 2-amine 
(SKA-268). SKA-268 was prepared from 2-bromoacetophenone 
(500 mg, 2.5 mmol) and [4-(trifluoromethyl)phenyl]thiourea 
according to General Method V. The product was isolated as 
yellow crystals (530 mg, 66%); m.p. = 153°C (CAS 1303995-
45-0). 1H NMR (800 MHz, DMSO-d6): δ = 10.75 (s, 1H), 
8.01 (m, 4H), 7.75 (d, J = 8.5 Hz, 2H), 7.49(m, 3H), 7.37 (m, 
1H). 13C NMR (201 MHz, DMSO-d6): δ = 162.8, 150.6, 144.8, 
134.7, 129.1, 128.2, 126.8, 126.8, 126.2, 125.8, 124.4, 123.1, 
116.9, 104.6.
5-Ethylnaphtho[1,2-d]thiazol-2-amine (SKA-306). SKA-306 
was prepared from 1-ethylnaphthalene in 3 steps according to 
General methods I, II, and VII. The product was isolated as a 
brownish powder. (154 mg, 22%); m.p = 144–145°C. 1H NMR (800 
MHz, DMSO-d6): δ = 8.39 (d, J = 7.7 Hz, 1H), 8.04 (d, J = 1.7 Hz, 
1H), 7.66 (s, 1H), 7.54–7.48 (m, 4H), 3.11–3.01 (m, 2H), 1.31 
(t, J = 7.5 Hz, 3H). 13C NMR (201 MHz, DMSO-d6): δ = 167.2, 
146.9, 133.2, 130.2, 126.5, 125.7, 125.4, 125.2, 124.5, 124.4, 118.3, 
25.7, 15.7. HRMS (ESI): m/z calculated for C13H12N2S (M+H)+: 
229.0794; found: 229.0794.
5-Propylnaphtho[1,2-d]thiazol-2-amine (SKA-307). SKA-
307 was prepared from 1-allylnaphthalene in 3 steps according to 
General Method I, II, and VII. The product was isolated as white 
crystals (495 mg, 70%); m.p. = 147–150°C. 1H NMR (800 MHz, 
DMSO-d6): δ = 8.41–8.33 (m, 1H), 8.07–7.98 (m, 1H), 7.65 (s, 1H), 
7.56–7.45 (m, 4H), 3.03–2.96 (m, 2H), 1.70 (q, J = 7.5 Hz, 2H), 0.98 
(t, J = 7.3 Hz, 3H).13C NMR (201 MHz, DMSO-d6): δ = 167.2, 147.2, 
131.5, 130.3, 126.6, 125.6, 125.3, 125.2, 124.6, 124.5, 119.3, 34.9, 
24.2, 14.5. HRMS (ESI): m/z calculated for C14H14N2S (M+H)+: 
243.0950; found: 243.0950.
5-Isopropylnaphtho[1,2-d]thiazol-2-amine (SKA-308). 
SKA-308 was prepared from 1-isopropylnaphthalene in 3 steps 
according to general method I, II, and VII. The product was 
isolated as white powder (179 mg, 10%); m.p. = 179–181°C.1H 
NMR (800 MHz, DMSO-d6): δ = 8.47–8.41 (m, 1H), 8.18–8.13 
(m, 1H), 7.77 (s, 1H), 7.59–7.52 (m, 4H), 1.38 (d, J = 6.8 Hz, 7H). 
13C NMR (201 MHz, DMSO-d6): δ = 167.3, 146.9, 137.6, 130.3, 
129.8, 126.6, 125.5, 125.4, 124.7, 124.0, 115.5, 28.4, 24.0. HRMS 
(ESI): m/z calculated for C14H14N2S (M+H)+: 243.0950; found: 
243.0949.
Naphtho[1,2-d:5,6-d’]bis(thiazole)-2,7-diamine (SKA-318). 
1,5-Diaminonaphthalene (500 mg, 3.16 mmol) and ammonium 
thioscyanate (480 mg, 6.32 mmol) were dissolved in 20 mL of 
anhydrous acetonitrile at room temperature. Benzyl trimethyl 
ammonium tribromide (2.48  g, 6.36 mmol) was added to 
the solution, and the reaction mixture was stirred at room 
temperature for 5  h. After completion of the reaction as 
determined by TLC, the reaction mixture was concentrated 
to dryness under vacuum, and the residue was diluted with 
100  ml of water. The pH of the solution was adjusted to 
between 7 to 7.5 with saturated sodium bicarbonate solution. 
The product was isolated as a red crystal (20 mg, 2.5%); m.p = 
194°C (CAS 1621401-78-2). 1H NMR (800 MHz, DMSO-d6): 
δ = 7.41 (d, J = 9.0 Hz, 2H), 7.38 (d, J = 9.0 Hz, 2H), 5.80 (s, 
4H). 13C NMR (201 MHz, DMSO-d6): δ = 168.1,141.8, 129.2, 
123.4, 112.3, 102.7.
5-Nitronaphtho[1,2-d]thiazol-2-amine (SKA-321). SKA-321 
was prepared from 1-naphtho[1,2-d]thiazol-2-amine (500 mg, 7 
mmol) according to General Method I. The product was isolated 
as white powder (30 mg, 2%); m.p. = 289–291°C (CAS 320340-
92-9) 1H NMR (800 MHz, DMSO-d6): δ = 8.95 (s, 1H), 8.67 (dt, 
J = 8.7, 0.9 Hz, 1H), 8.54 (dd, J = 8.3, 1.6 Hz, 1H), 8.40 (s, 2H), 
7.76 (ddd, J = 8.6, 6.8, 1.4 Hz, 1H), 7.69 (ddd, J = 8.1, 6.8, 1.1 Hz, 
1H). 13C NMR (201 MHz, DMSO-d6): δ = 173.2, 155.2, 138.5, 
129.3, 127.1, 125.2, 125.1, 124.8, 123.7, 121.4.
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5-Phenylnaphtho[1,2-d]thiazol-2-amine (SKA-326). SKA-326 
was prepared from 1-phenylnaphthalene in 3 steps according to 
General Method I, II, and VII. The product was isolated as white 
crystals (495 mg, 78%); m.p. = 177–178°C 1H NMR (800 MHz, 
DMSO-d6): δ = 8.43 (d, 1H), 7.78 (dt, J = 8.5, 0.9 Hz, 1H), 7.74 
(s, 1H), 7.68 (s, 2H), 7.57–7.50 (m, 3H), 7.50–7.46 (m, 2H), 7.48–
7.42 (m, 2H).13C NMR (201 MHz, DMSO-d6): δ = 168.1, 148.2, 
140.8, 133.0, 130.4, 130.0, 128.8, 127.5, 126.3, 126.1, 126.0, 125.7, 
125.3, 124.4, 120.5. HRMS (ESI): m/z calculated for C17H12N2S 
(M+H)+: 277.0794; found: 277.0798.
N5,N5-Diethylnaphtho[1,2-d]thiazole-2,5-diamine (SKA-
330). SKA-330 was prepared from diethylamine hydrochloride 
in 3 steps according to General Method II, VI, and VII. The product 
was isolated as yellowish crystals (50 mg, 8%); m.p. = 119–121°C.1H 
NMR (800 MHz, DMSO-d6): δ = 8.32 (d, 1H), 8.27 (d, 1H), 7.60 
(s, 1H), 7.50 (ddd, J = 8.1, 6.7, 1.3 Hz, 1H), 7.45 (ddd, J = 8.2, 6.7, 
1.4 Hz, 1H), 7.43 (s, 2H), 3.09 (q, J = 7.1 Hz, 4H), 0.95 (t, J = 7.1 Hz, 
6H). 13C NMR (201 MHz, DMSO-d6): δ = 167.0, 145.0, 141.6, 130.3, 
126.9, 125.9, 125.4, 124.9, 124.59, 124.1, 112.7, 48.4, 21.5, 12.9. 
HRMS (ESI): m/z calculated for C15H17N3S (M+H)+: 272.1216; 
found: 272.1217.
N5,N5-Dimethylnaphtho[1,2-d]thiazole-2,5-diamine (SKA-
331). SKA-331 was prepared from dimethylamine hydrochloride 
in 3 steps according to General Method II, VI, and VII. The 
product was isolated as white crystals (30 mg, 5%); m.p. = 171–
174°C. 1H NMR (800 MHz, DMSO-d6): δ = 8.32 (d, 1H), 8.17 
(d, 1H), 7.51 (d,1H), 7.51 (s, 1H), 7.48 (d,1H), 7.42 (s, 2H), 2.78 
(s, 6H). 13C NMR (201 MHz, DMSO-d6): δ = 166.7, 145.2, 144.4, 
127.5, 127.0, 126.0, 125.4, 124.9, 124.5, 124.3, 108.8, 45.7 
HRMS (ESI): m/z calculated for C13H13N3S (M+H)+: 244.0903; 
found: 244.0902.
5-(1H-Imidazol-1-yl)naphtho[1,2-d]thiazol-2-amine (SKA-
334). SKA-334 was prepared from imidazole in 3 steps according 
to General Method II, VI, and VII. The product was isolated as 
brownish powder (130 mg, 19%); m.p. = 272–275°C. 1H NMR 
(800 MHz, DMSO-d6): δ = 8.46 (d, 1H), 7.99 (s, 1H), 7.94 (t, J 
= 1.1 Hz, 1H), 7.85 (s, 2H), 7.62 (ddd, J = 8.1, 6.8, 1.1 Hz, 1H), 
7.55–7.50 (m, 1H), 7.33 (dt, J = 8.4, 0.9  Hz, 2H), 7.18 (t, J = 
1.1 Hz,1H). 13C NMR (201 MHz, DMSO-d6): δ = 169.3, 149.1, 
139.3, 129.1, 128.4, 127.2, 126.9, 126.8, 125.8, 124.5, 124.4, 123.0, 
122.6, 118.6. HRMS (ESI): m/z calculated for C14H10N4S (M+H)+: 
267.0699; found: 267.0700.
5-(1H-Pyrazol-1-yl)naphtho[1,2-d]thiazol-2-amine (SKA-
335). SKA-335 was prepared from pyrazole in 3 steps according 
to General methods II, VI, and VII. The product was isolated 
as brown crystal (220 mg, 31%); m.p. = 226–227°C. 1H NMR 
(800 MHz, DMSO-d6): δ = 8.44 (dt, J = 8.3, 1.1 Hz, 1H), 8.12 (d, 
J = 2.3 Hz, 1H), 7.97 (s, 1H), 7.85–7.80 (m, 3H), 7.60 (ddd, J = 
8.2, 4.7, 3.2 Hz, 1H), 7.52–7.47 (m, 2H), 6.57 (t, J = 2.1 Hz, 1H). 
13C NMR (201 MHz, DMSO-d6): δ = 169.2, 149.0, 140.6, 133.2, 
130.8, 128.2, 126.7, 126.5, 125.9, 124.3, 124.2, 123.6, 118.1, 106.7. 
HRMS (ESI): m/z calculated for C14H10N4S (M+H)+: 267.0699; 
found: 267.0700.
5-(1H-1,2,3-Triazol-1-yl)naphtho[1,2-d]thiazol-2-amine 
(SKA-339). SKA-339 was prepared from 1,2,3-triazole in 3 steps 
according to General methods II, VI, and VII. The product was 
isolated as purplish crystals (120 mg, 17%); m.p = 208°C. 1H 
NMR (800 MHz, DMSO-d6): δ = 8.48 (d, Hz,1H), 8.20 (s, 2H), 
8.15 (s, 1H), 7.91 (s, 2H), 7.66–7.61 (m, 2H), 7.54 (ddd, J = 8.3, 
6.7, 1.3 Hz, 1H). 13C NMR (201 MHz, DMSO-d6): δ = 169.8, 149.7, 
136.3, 130.2, 126.9, 126.9, 126.8, 125.7, 124.4, 124.2, 123.3, 118.2. 
HRMS (ESI): m/z calculated for C13H9N5S (M+H)+: 268.0651; 
found: 268.0654.
5-(3-Methyl-1H-pyrazol-1-yl)naphtho[1,2-d]thiazol-2-amine 
(SKA-340). SKA-340 was prepared from 3-methylpyrazole in 3 
steps according to General methods II, VI, and VII. The product was 
isolated as brownish crystals (140 mg, 19%); m.p = 189–190°C. 1H 
NMR (800 MHz, DMSO-d6): δ = 8.46–8.41 (m, 1H), 7.97 (d, J = 
2.2 Hz, 1H), 7.92 (s, 1H), 7.81 (s, 2H), 7.61–7.57 (m, 2H), 7.50 
(ddd, J = 8.4, 7.0, 1.3 Hz, 1H), 6.35 (d, J = 2.2 Hz, 1H), 2.31 (s, 
3H). 13C NMR (201 MHz, DMSO-d6): δ = 169.1, 149.0, 148.7, 
133.8, 131.0, 128.1, 126.6, 126.4, 125.9, 124.3, 124.2, 123.8, 117.9, 
106.4,13.9. HRMS (ESI): m/z calculated for C15H12N4S (M+H)+: 
281.0855; found: 281.0858.
5-(3-(Trifluoromethyl)-1H-pyrazol-1-yl)naphtho[1,2-d]
thiazol-2-amine (SKA-341). SKA-341 was prepared from 
3-(trifluoromethyl)pyrazole in 3 steps according to General methods 
II, VI, and VII. The product was isolated as white crystals (150 mg, 
17%); m.p = 206–207°C. 1H NMR (800 MHz, DMSO-d6): δ = 8.47 
(dt, J = 8.3, 1.0 Hz, 1H), 8.41 (dd, J = 2.4, 1.1 Hz, 1H), 8.11 (s, 1H), 
7.91 (s, 2H), 7.63 (ddd, J = 8.2, 6.7, 1.2 Hz, 1H), 7.55 (ddd, J = 8.3, 6.8, 
1.3 Hz, 1H), 7.37 (dt, J = 8.5, 0.9 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H).13C 
NMR (201 MHz, DMSO-d6): δ = 169.8, 149.8, 142.4, 136.0, 129.4, 
127.8, 127.1, 126.9, 125.7, 124.5, 124.1, 122.7, 122.6, 118.9, 105.5. 
HRMS (ESI): m/z calculated for C15H9F3N4S (M+H)+: 335.0573; 
found: 335.0575.
5-(4-Methyl-1H-imidazol-1-yl)naphtho[1,2-d]thiazol-
2-amine (SKA-343). SKA-343 was prepared from 
4-methylimidazole in 3 steps according to General methods II, 
VI, and VII. The product was isolated as brownish crystals (160 
mg, 22%); m.p = 269–271°C. 1H NMR (800 MHz, DMSO-d6): δ = 
8.45 (d, 1H), 7.95 (d,1H), 7.86 (s, 1H), 7.82 (s, 2H), 7.77 (d, 1H), 
7.63–7.58 (m, 1H), 7.52 (dtd, J = 7.6, 6.5, 1.3 Hz, 1H), 7.39 (dt, J 
= 8.4, 0.9 Hz, 1H), 2.23 (d, J = 1.1 Hz, 3H). 13C NMR (201 MHz, 
DMSO-d6): δ = 169.4, 169.1, 148.9, 139.0, 138.5, 137.5, 128.4, 
127.5, 126.8, 126.8, 126.8, 126.4, 125.8, 124.5, 124.4, 124.4, 122.8, 
122.6, 119.9, 119.2, 118.3, 55.3, 14.1. HRMS (ESI): m/z calculated 
for C15H12N4S (M+H)+: 281.0855; found: 281.0859.
5-(2-Methyl-1H-imidazol-1-yl)naphtho[1,2-d]thiazol-
2-amine (SKA-344). SKA-344 was prepared from 
2-methylimidazole in 3 steps according to General methods 
II, VI, and VII. The product was isolated as light brown 
powder (300 mg, 41%); m.p = 264–265°C. 1H NMR (800 MHz, 
DMSO-d6): δ = 8.46 (ddd, J = 8.2, 1.2, 0.7 Hz, 1H), 7.97 (s, 1H), 
7.87 (s, 2H), 7.61 (ddd, J = 8.1, 6.8, 1.2  Hz, 1H), 7.51 (ddd, 
J = 8.2, 6.8, 1.3  Hz, 1H), 7.28 (d, J = 1.3  Hz, 1H), 7.05 (dt, 
J = 8.4, 0.9  Hz, 1H), 7.02 (d, J = 1.3  Hz, 1H), 2.03 (s, 3H). 
13C NMR (201 MHz, DMSO-d6): δ = 169.4, 149.3, 145.8, 128.8, 
127.5, 127.2, 127.0, 126.8, 126.0, 124.5, 124.5, 123.1, 122.6, 119.5, 
13.2. HRMS (ESI): m/z calculated for C15H12N4S (M+H)+: 281.0855; 
found: 281.0859.
5-(4-Methyl-1H-pyrazol-1-yl)naphtho[1,2-d]thiazol-2-amine 
(SKA-345). SKA-345 was prepared from 4-methylpyrazole in 3 
steps according to General methods II, VI, and VII. The product was 
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isolated as brownish powder (280 mg, 39%); m.p = 249°C. 1H NMR 
(800 MHz, DMSO-d6): δ = 8.43 (dt, J = 8.3, 0.9 Hz, 1H), 7.97 (s, 
1H), 7.92 (s, 1H), 7.87 (t, J = 0.9 Hz, 1H), 7.81 (s, 2H), 7.62–7.54 
(m, 2H), 7.49 (ddd, J = 8.3, 6.7, 1.3 Hz, 1H), 2.16 (s, 3H). 13C 
NMR (201 MHz, DMSO-d6): δ = 169.1, 148.8, 141.2, 131.6, 
131.1, 128.1, 126.6, 126.4, 125.9, 124.3, 123.7, 117.8, 116.3, 9.2. 
HRMS (ESI): m/z calculated for C15H12N4S (M+H)+: 281.0855; 
found: 281.0857.
5-(1H-1,2,4-Triazol-1-yl)naphtho[1,2-d]thiazol-2-amine 
(SKA-347). SKA-347 was prepared from 1,2,4-triazole in 3 steps 
according to General methods II, VI, and VII. The product was 
isolated as light yellowish crystals (200 mg, 28%); m.p = 273°C. 
1H NMR (800 MHz, DMSO-d6): δ = 8.97 (s, 1H), 8.47 (dt, J = 8.3, 
1.0 Hz, 1H), 8.33 (s, 1H), 8.08 (s, 1H), 7.92 (s, 2H), 7.63 (ddd, J = 8.1, 
6.8, 1.1 Hz, 1H), 7.54 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H), 7.42 (dt, J = 8.5, 
0.9 Hz, 1H). 13C NMR (201 MHz, DMSO-d6): δ = 169.7, 152.6, 
149.8, 146.6, 127.8, 127.0, 126.9, 126.7, 125.84, 124.4, 124.1, 
122.9, 118.8. HRMS (ESI): m/z calculated for C13H9N5S (M+H)+: 
268.0651; found: 268.0655.
Crystal Structure Determination
The SKA-218, SKA-339, SKA-340, SKA-343 and SKA347 
crystals selected for data collection were mounted and 
optically centered in a nitrogen low temperature stream 
–183°C (90K), on the Bruker diffractometer with an APEX2 
CCD detector or a Bruker D8 Venture diffractometer equipped 
with a Photon100 CMOS detector (Bruker, Madison, WI). 
Data were collected with the use of Mo Ka radiation in all cases 
(λ = 0.71073 Å). The structures were solved by direct methods 
(SHELXT) and refined by full-matrix least-squares on F2 
(SHELXL-2018/3). All non-hydrogen atoms were refined with 
anisotropic displacement parameters. For a description of the 
method, see (Sheldrick, 2008).
Crystal Data SKA-218, JF2786, APEX2, C12H7N3O4S, F.W  = 
289.27, purple block, dimensions = 0.472 x 0.400 x 0.232 mm3, 
monoclinic, P21/n, a = 9.9178(15) Å, b = 15.885(2) Å, c  = 
7.4528(11) Å, β = 93.4141(19)°, V = 1172.0(3) Å3, Z = 4, 182 
parameters, 0 restraints.
Crystal Data SKA-339, JF2770, D8 Venture, C13H9N5S, F.W 
= 267.31, yellow plate, dimensions = 0.136 x 0.071 x 0.023 
mm3, monoclinic, P21/n, a = 16.3915(19) Å, b = 3.7972(4) Å, 
c = 19.437(2) Å, β = 112.065(2)°, V = 1121.2(2) Å3, Z = 4, 208 
parameters, 0 restraints.
Crystal Data SKA-340, JF2772, D8 Venture, C15H12N4S, F.W = 
280.35, yellow rod, dimension = 0.401 x 0.143 x 0.073 mm3, 
triclinic, P-1, a = 8.7703(10) Å, α = 96.219(4)°, b = 9.3235(11) 
Å, β  = 103.017(4)°, c = 10.7112(13) Å, γ = 110.077(4)°, V = 
784.83(16) Å3, Z = 2, 237 parameters, 0 restraints.
Crystal Data SKA-343, JF2787, D8 Venture, C15H12N4S F.W = 
280.35, colorless rod, dimensions = 0.221 x 0.086 x 0.051 mm3, 
monoclinic, P21/n, a = 15.9106(10) Å, b = 20.4896(13) Å, 
c = 7.9634(5) Å, β = 94.589(2)°, V = 2587.8(3) Å3, Z = 8, 458 
parameters, 0 restraints.
Crystal Data SKA-347, JF2769, D8 Venture, C13H9N5S, F.W. = 
267.31, colorless block, dimensions = 205 x 0.150 x 0.088 mm3, 
monoclinic P21/n a = 3.7801(3) Å, b = 14.7453(12) Å, c = 20.2851(17) 
Å, β = 94.550(2)°, V = 1127.10(16) Å3, Z = 4, R1 = 0.0305, wR2 = 
0.0797, 209 parameters, 0 restraints.
RESULTS
Structure-Based Drug Design Using the 
Crystal Structure of the KCa2.2 CaM-BD/
CaM Interface
We previously generated homology models of KCa3.1 and KCa2.3 
(Brown et al., 2017) using the Rosetta membrane method 
(Rohl et al., 2004; Bender et al., 2016; Alford et al., 2017) and 
the x-ray crystal structure of the KCa2.2 CaM-BD/CaM (Zhang 
et al., 2013) as a template. We localized the binding site of the 
benzothiazoles/oxazoles to the CaM-BD/CaM interface and 
generate models of the KCa3.1 and KCa2.3 CaM-BD/CaM complexes 
with SKA-121 and SKA-111 using Rosetta Ligand docking (Meiler 
and Baker, 2006; Davis and Baker, 2009; Bender et al., 2016). The 
docking models of KCa3.1 showed that the amino groups of the 
benzoxazole ring of SKA-121 and of the benzothiazole ring of 
SKA-111 form hydrogen bonds with M51 and E54 in calmodulin 
(Brown et al., 2017). Moreover, E54 was further stabilized by an 
extensive hydrogen bond network with R362, E295 and N300 
in the KCa3.1 channel, which we hypothesized to be responsible 
for the KCa3.1 selectivity of SKA-121 and SKA-111. In the KCa2.3 
or KCa2.2 model, however, SKA-111 and SKA-121 formed only 
hydrogen bonds with M51 and E54, due to the shorter length of 
the sidechain of S622 in KCa2.3 or N474 in KCa2.2 than that of the 
corresponding R362 in KCa3.1 (Supplementary Figure 1).
Using the information from these computational docking 
models, we here intended to design new KCa2 selective activators 
by attempting to predict whether the compounds would show 
selectivity for KCa2 over KCa3.1 channels. However, instead of our 
previously generated KCa2.3 CaM-BD/CaM homology model, 
we here used a KCa2.2 CaM-BD/CaM model based on the KCa2.2 
CaM-BD/CaM-NS309 crystal structure (pdb:4J9Z). We made this 
switch because KCa2.2 is the most abundantly expressed KCa2 channel in 
the mammalian CNS (Adelman et al., 2012) and therefore constitutes 
an attractive target for the treatment of ataxia and epilepsy. We 
additionally docked eight more 2-amino-naphthobenzothiazole 
derivatives (SKA-31, SKA-44, SKA-45, SKA-72, SKA-73, 
SKA-107, SKA-117, and SKA-120) into the KCa2.2 and KCa3.1 
homology models and found that these compounds exhibited 
the same hydrogen bond network as SKA-121 and SKA-111 in 
KCa3.1 (Supplementary Figure 1). Based on these docking poses 
we hypothesized that disruption of the hydrogen bond between 
the –NH2 group of the benzothiazole ring, and the CaM M51 
and E54 residues, which are present in both the KCa3.1 and KCa2.2 
models, might be a way to achieve KCa2.2 selectivity. Our goal here 
was to first “break” this hydrogen bond to ideally achieve KCa2.2 
selectivity and then regain potency by adding substituents in 
other positions to pick up unique contacts in KCa2.2. We therefore 
virtually added various substituents in the C-4,5,6,7,8,9 positions 
of SKA-74 (Figure 1A), a compound which contains a methyl 
group in C-2 position instead of an -NH2 group and which we 
had previously found to activate KCa2 and KCa3.1 channels with a 
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similar ~30 μM potency (Coleman et al., 2014). To improve van 
der Waals contacts we introduced -CH3, -Br, -Cl, -CF3 groups. 
The C-5 position was chosen for the first trial since the KCa2.2 
docking model of SKA-74 showed that it is adjacent to A484 
and in range for new interactions. We also virtually introduced 
larger substituents such as cyclohexyl, cyclopentyl, cyclopropyl 
and phenyl on the 2-position amino group because the KCa2.2 
model showed more space in this region of the binding site than 
FIGURE 1 | Design scheme of KCa2.2 selective activators and Rosetta models of the top 10 binding poses with the lowest energy of template compounds in the 
interface between CaM (pink) and the CaM-BD (light green) of KCa3.1 and KCa2.2. The docking model of SKA-74 (A) and SKA-76 (B) showed that the ten lowest 
binding energy scored models exhibit good structural convergence in KCa2.2 but not in KCa3.1 suggesting selectivity for KCa2.2 over KCa3.1.
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the KCa3.1 model. In addition, we also virtually generated double 
substituted SKA-74 derivatives (a bulky substituent in the C-2 
position and methyl in C-5 position). In parallel we designed a 
small focused library of 2-aminothiazoles (SKA-75 and SKA-76 
derivatives; Figure 1B). Our reasoning for the choice of these two 
compounds as additional templates was that SKA-75, like SKA-
74, had previously been found to be of similar potency (~30 μM) 
on both KCa2.3 and KCa3.1, and that SKA-76 was slightly more 
potent on KCa2.3 (~25 μM) than KCa3.1 (~50 μM) (Coleman et 
al., 2014). In addition, the molecular docking models of SKA-
75 and SKA-76, which both lack the continuous conjugation 
between the naphthalene and the 2-aminothiazole ring (Figure 1 
right), showed that the ten lowest energy scored models exhibited 
good structural convergence in KCa2.2 but not in KCa3.1 (Figure 
1B). In order to improve the potency and selectivity of SKA-75 
and SKA-76 we virtually added a methyl group in the 2,3,4,5,6,7 
or 8 positions of the naphthalene ring in SKA-75 and SKA-76. 
We then replaced the naphthalene ring with a bi-phenyl ring, a 
2-aminophenylthiazole or a 2-aminobiphenylthiazole. We further 
replaced the naphthalene ring with a phenyl ring and added larger 
groups such as N-trifluorophenyl, N-pyridine to the -NH2 group 
of the 2-aminothiazole ring.
The virtually proposed 63 SKA-74 derivatives, 87 SKA-75 
and SKA-76 derivatives as well as another 18 SKA-31-related 
compounds (see Supplementary Figure 2 for all structures) were 
randomly placed into the KCa2.2 and KCa3.1 homology models of 
the CaM-BD/CaM interface pocket, energy minimized through 
the three stages of the RosettaLigand method, and the top 10 
lowest binding energy scoring models were analyzed. SKA-74 
derivatives with –CH3, -CF3, -Br and –Cl in 5-position were 
predicted to show selectivity for KCa2.2 channels over KCa3.1 
(Figures 2A, B) because they converged well in the KCa2.2 model 
and made van der Waals interactions (dark purple in Figure 2B) 
with A477, V481 in KCa2.2 and M72, F68, I63 and M51 in CaM. In 
contrast, the top 10 lowest energy models of all SKA-74 derivatives 
with bulky substituents in C-2 position did not converge in either 
KCa2.2 or KCa3.1, whereas all double substituted SKA 74 derivatives 
were predicted to be KCa2.2 selective with good structural 
convergence in KCa2.2. For the SKA-75 and SKA 76 derivatives, the 
docking model suggested that addition of a methyl group to the 
6-position of the naphthalene ring in SKA 76 (SKA-198) created 
new hydrogen bonds and good structural convergence in the 
KCa2.2 model but not in KCa3.1. Replacement of the naphthalene 
ring of SKA-75 with a bi-phenyl ring, a 2-aminophenylthiazole 
FIGURE 2 | Rosetta ligand docking models of the lowest energy-binding poses of SKA-130 (A, B) and SKA-230 (C, D) in the interface between CaM (pink) and 
CaM-BD (light green) of KCa3.1 and KCa2.2. Hydrogen bonds and van der Waals interactions are indicated by purple and black lines. (A, B) Molecular docking 
suggests that SKA-130 converged well and formed several van der Waals contacts in KCa2.2 but not in KCa3.1. (C, D) Both KCa3.1 and KCa2.2 models exhibited 
good structural convergence. The molecular docking model showed that while SKA-230 only formed 2 hydrogen bonds in KCa3.1, it formed four hydrogen bonds in 
KCa2.2 suggesting selectivity for KCa2.2.
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or a 2-aminobiphenylthiazole (SKA-232, SKA-230 and SKA-255) 
created new hydrogen bonds and good structural convergence in 
both KCa2.2 and KCa3.1. The molecular docking model showed 
that while these SKA-75 derivatives (SKA-232, SKA-230 and 
SKA-255) only formed 2 hydrogen bonds in KCa3.1, they formed 
four hydrogen bonds in KCa2.2 (see Figures 2C, D for SKA-230) 
suggesting selectivity for KCa2.2 as well as relatively high potency.
Synthesis and Activity Testing of the 
Newly Designed KCa Channel Activators
Based on the docking models we chose 26 (16 SKA-74 and 
10 SKA-75/76 derivatives) of the 168 virtual compounds 
for synthesis including some that were not predicted 
to be selective in order to verify that the predicted 
selectivity in the model is consistent with experiments (see 
Supplementary Figure 2 where the chosen structures are 
highlighted in color). A general scheme of the compound 
synthesis is given in Figure 3. To obtain 5-CH3 substituted 
SKA-74 derivatives the commercially available starting 
materials, 2-methylnaphtho[1,2-d]thiazole (SKA-74) and 
2-methylnaphtho[1,2-d]oxazole (SKA-103), were first 
brominated using liquid bromine to obtain SKA-132 and SKA-
133, which were then reacted with CuCN in a cross coupling 
reaction with a palladium catalyst to obtain SKA-126 and 
SKA-135. SKA-130 was synthesized by electrophilic aromatic 
FIGURE 3 | General scheme for the synthesis of SKA-74, SKA-75, SKA-76 (A) and SKA-111 derivatives (B).
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substitution with N-chlorosuccinimide. N-substituted SKA-
74 derivatives were prepared from 1-aminonaphthalene, 
which was reacted with isothiocyanates to the N,N’-
disubstituted thioureas, which were then cyclized using 
bromine. SKA  75 and SKA-76 derivatives were synthesized 
starting from methyl naphthalene, 1,4 acetylbenzene, 
1-acetonaphthone or 2-bromo substituted acetophenone. 
A classic Fridel-Craft acylation was used to synthesize 
monoacylated intermediates, which were then brominated on 
the alpha carbon followed by cyclization of the compounds 
with substituted thiourea and liquid bromine.
The newly synthesized compounds were tested by automated 
whole-cell patch-clamp for their ability to activate KCa2.2 and 
KCa3.1 channels stably expressed in HEK cells. In order to 
quickly identify promising compounds, we devised a screening 
system in which we measured the response of each compound 
at a concentration of 10 µM and normalized that response 
to the response elicited by 10 µM of SKA-31, which at this 
concentration maximally activates both KCa3.1 and KCa2.2 
(Sankaranarayanan et al., 2009). This screen was performed at a 
free intracellular Ca2+ concentration of 250 nM, which is ideal 
for activator testing (Jenkins et al., 2013), and therefore allowed 
us to determine two things; (1) if each compound could elicit a 
maximal effect, and (2) if a compound displayed any selectivity 
towards KCa2.2. A promising compound would ideally do both. 
Supplementary Figure 3 shows representative raw current 
traces to illustrate the sequence and timing of compound 
additions and washes. We started by comparing the effect of 
the SKA-74 derivatives to SKA-31 (Figure 4A). Addition of a 
cyanide group to the C5-position (SKA-135) or of a nitro group 
to the 6-position (SKA-215), rendered the compounds inactive 
on both channels. Introduction of lipophilic chloro- or bromo-
groups (SKA-130, SKA-132 and SKA-133), decreased activity on 
KCa2.2 but preserved selectivity for KCa3.1. Similarly, adding –
NH2 or –NO2 groups in the 6- or 9- or both the 5- and 6-position 
preserved the selectivity for KCa3.1 (SKA-172, SKA-178, SKA-
216 and SKA-218). Substitution of the 2-position -NH2 group 
also did not result in any KCa2.2 selective compounds. While 
introduction of a -CH3 group (SKA-158) abolished activity 
on KCa2.2 but preserved it again on KCa3.1, introduction of an 
aromatic phenyl (SKA-146) or a cyclopropyl (SKA-169) ring 
rendered the resulting compounds less potent than SKA-31. 
Introduction of a larger, aliphatic cyclohexyl group (SKA-165) 
completely eliminated activity on both channels.
We next tested the linear SKA-75 and SKA-76 derivatives 
and found that, compared to their undecorated templates, 
introduction of a methyl or a bromo group to SKA-75 
and SKA  76 (SKA-190, SKA-193, SKA-198 and SKA-
220) somewhat increased KCa channel activating potency 
(Figure 4B). However, when compared to SKA-31, none of 
these modifications produced the desired KCa2.2 selectivity 
or improved potency. Additional introduction of a large 
substituent on the -NH2 group completely abolished activity 
(SKA-251 and SKA-258). Similarly, various linearized 
compounds (SKA-230, SKA-232, SKA-255, SKA-260, SKA-265 
and SKA-268) were completely devoid of activity even though 
RosettaLigand docking predicted these linear compounds to 
be KCa2.2 selective and potent based on multiple predicted 
hydrogen bonds (see Figure 2D for SKA-230 in KCa2.2).
Return to “Classical Medicinal” Chemistry
At this stage of our work we became very skeptical about our 
approach of using RosettaLigand docking for structure based 
KCa2.2 activator design and decided to return to a purely 
activity driven compound design approach. We therefore 
went back to the 2-aminonaphothiazole system of SKA-31 
and opted to further exploit our previous observation that 
introduction of a single -CH3 group in 5-position could 
achieve a 100-fold gain in selectivity for KCa3.1 over KCa2 
channels (Coleman et al., 2015). In order to more thoroughly 
explore the structure-activity relationship (SAR) in the 
5-position (Figure 5A) we replaced the methyl group of 
SKA-111 with longer alkyl chains such as ethyl (SKA-306), 
propyl (SKA-307), isopropyl (SKA-308) or other functional 
groups, which were not tried in our previous study such 
sulfonyl (SKA-128), nitro (SKA-321), dimethyl (SKA-330) 
or diethylamino (SKA-331). We further decided to generate 
a small library of compounds with aromatic substituents in 
5-position such as phenyl, imidazole, pyrazole, and triazole 
in order to provide ample possibilities to pick up new van 
der Waals, π–π, cation–π or hydrogen bond interactions 
(Figure  5B). In total we synthesized 19 SKA-111 
derivatives according to the schemes shown in Figure 3B. 
Alkyl or phenyl substituted compounds were synthesized 
starting from differently substituted naphthalenes, which 
we first nitrated using nitric acid and then reduced with 
hydrazine. Finally, to obtain the benzothizole ring-
system the resulting amino-substituted naphthalenes were 
subjected to a classic Hugerschoff benzothiazole synthesis 
with potassium thiocyanate and liquid bromine. Secondary 
amines or heterocyclic ring substituted compounds were 
prepared from 1-fluoro-4-nitronaphthalen, which was 
reacted with differently substituted amines through amine 
arylation. This nucleophilic aromatic substitution allowed 
us to introduce the heterocycle ring system or alkylamine 
into the 5-position of the naphthalene ring. Other 
2-aminobenzothiazoles were generated through nitration 
and Hugerschoff benzothiazole synthesis.
We next proceeded to screen these SKA-111 derivatives 
(Figure 5) and found that replacement of the 5-position 
methyl group with ethyl (SKA-306), propyl (SKA-307), 
isopropyl (SKA-308) and dimethylamine (SKA-331) resulted 
in compounds that were roughly as potent and as KCa3.1 
selective as SKA-111. Addition of a diethylamine group 
(SKA-330) somewhat reduced potency, while large, polar 
substituents like a nitro-group (SKA-312) or a sulfonic acid 
(SKA-128) drastically reduced potency on both KCa3.1 and 
KCa2.2. Unfortunately, introduction of aromatic substituents 
in 5-positions also did not provide any KCa2.2 selective 
compounds and overall again reduced potency on both 
channels. Taken together, we failed to generate any KCa2.2 
selective SKA compounds using either structure based or 
“classical” approaches.
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FIGURE 4 | Whole-cell KCa3.1 and KCa2.2 responses elicited by 10 µM of activator and normalized to 10 µM of the mixed activator SKA-31. Experiments were 
performed by automated electrophysiology with 250 nM of free internal Ca2+. In each experiment the new activator was tested first, washed out with 2 saline 
additions, and then SKA-31 was applied as positive control for normalization of the response. (A) Screening of SKA-74 derivatives. (B) Screening of SKA-75 and 
SKA-76 derivatives. The bar graphs show means ± SD of the slope conductance measured between －85 and －65 mV (n = 2–7 cells). Chemical structures are 
shown below the bar graphs.
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FIGURE 5 | Whole-cell KCa3.1 and KCa2.2 responses elicited by 10 µM of activator and normalized to 10 µM of the mixed activator SKA-31. Experiments were 
performed by automated electrophysiology with 250 nM of free internal Ca2+. In each experiment the new activator was tested first, washed out with 2 saline 
additions, and then SKA-31 was applied as positive control for normalization of the response. (A) Screening of SKA-111 derivatives. (B) Screening of aromatically 
substituted SKA-111 derivatives. The bar graphs show means ± SD of the slope conductance measured between －85 and －65 mV (n = 2–7 cells). Chemical 
structures are shown below the bar graphs.
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The Full-Length KCa3.1 Cryo-EM Structure 
Reveals That the C-Terminal CaM-BD/
CaM Dimer Crystal Is an Artefact
In our structure-based drug design attempt described above, 
we had used the C-terminal CaM-BD/CaM crystal structure, 
which consist of two vertically orientated CaM molecules and 
two horizontal KCa2.2 C-terminal fragments in an antiparallel 
arrangement (Zhang et al., 2012). In this structure, the CaM 
N-lobe interacts with the C-terminal region of the CaM-BD, 
whereas the C-lobe is bound to N-terminal region of the CaM-BD. 
Several KCa channel activators, EBIO (Zhang et al., 2012), NS309 
(Zhang et al., 2013) and, most recently in a publication from the 
Structural Biology group at Pfizer (Cho et al., 2018), CyPPA and 
riluzole were shown by X-ray crystallography and solid-state 
NMR to be located at the interface between the CaM N-lobe 
and the C-terminal region of the CaM-BD, where we docked 
our compounds. For clarity, only half of this so-called “dimer of 
dimers” complex, one CaM and one C-terminal fragment, was 
used for our modeling (see Supplementary Figure 1).
Recently, the MacKinnon group (Lee and MacKinnon, 2018) 
determined the full-length cryo-EM structures of KCa3.1 in the 
closed and in two activated states (pdb: 6cnm, 6cnn, and 6cno) 
and revealed that the C-terminal CaM-BD/CaM dimer crystal 
is an artefact. The full-length structure showed four CaMs per 
channel tetramer, with the CaM C-lobe of each CaM tightly 
bound to the CaM-BD of each subunit in the closed and the 
two activated states (Figure 6A). However, the N-lobes were 
only clearly visible in the open, Ca2+-bound states and poorly 
resolved in the closed, Ca2+-free structure suggesting that they 
are flexible in the absence of Ca2+. When Ca2+ binds to the N-lobe 
it moves from the bottom of the S2 segment to the bottom of the 
S4-S5 linker (which in KCa3.1 consists of two helices), while the 
C-lobe maintains its interaction with the HA and HB helices in 
the C-terminus. The N-lobe then pulls part of the S4–S5 linker, 
namely the S45A helix downward and this displacement expands 
the S6 helices and opens the pore (Lee and MacKinnon, 2018). In 
their study the MacKinnon group also proposed a new binding 
pocket for the KCa activator EBIO formed by the S45A helix and 
the CaM N-lobe, in which EBIO binds to L185 in the S45A linker 
(Lee and MacKinnon, 2018) instead of L480 in the C-terminal 
crystal complex (Zhang et al., 2012). However, this very plausible 
alternative binding site hypothesis was not experimentally tested.
Probing the “New” SKA Compound 
Binding Site at the Interface Between the 
S45A Helix and the CaM N-Lobe
Based on this new binding site hypothesis we here docked and 
energy minimized SKA-111 in the interface pocket between the 
S45A helix and the CaM N-lobe (Figure 6A) using the open state 
of the full length cryo-EM structure of KCa3.1. The two open 
cryo-EM structures (6cnn and 6cno) were refined using the 
Rosetta cryo-EM refinement protocol with cryo-EM density map 
(Wang et al., 2016). A total of 10,000 models were generated for 
each state and the model with the lowest energy among the largest 
clusters of the top 1,000 models was used for RosettaLigand 
docking of SKA-111 starting from random ligand positions at the 
interface between the S45A helix and the CaM N-lobe. Similar to 
our previous docking model, SKA-111 is stabilized in open state 
1 by hydrogen bonds involving M51 and E54 and multiple CaM 
N-lobe residues are located within a 5 Å radius sphere around 
SKA-111 (F19, I27, L32, M51, I52, E54 V55, I63, F68, M71, M72, 
R74, K75) (Figure 6A, open state 1). However, on the channel 
side SKA-111 now makes van der Waals interactions with S181 
and L185 in the S45A helix (Figure 6A). Interestingly, in open 
state 2 the lowest energy docking pose of SKA-111 is “flipped” 
180 degrees around the hydrogen bond with CaM M51 and the 
molecule now makes van der Waals contacts with S181 and A184 
in the S45A helix and again multiple residues in the CaM N-lobe 
(Supplementary Figure 4). The parent compound SKA-31 and 
the benzoxazole SKA-121 take up similar low energy docking 
poses in which they make contacts with M51 and E54 in CAM 
and S181 and/or L185 in KCa3.1 (Supplementary Figure 5).
In order to probe this “new” binding site we decided to 
mutate S181, L185 and the neighboring A184 to smaller, bulkier 
or charged residues to either disrupt contacts with SKA-111 or 
disturb the overall shape and size of the S45A helix/CaM N-lobe 
interface pocket. As described in the Materials and Methods, 
mutations were first tested for expression and Ca2+ sensitivity 
and then used for evaluation of SKA-111 sensitivity. Mutating 
serine 181 to a shorter alanine, reduced SKA-111 potency 
7-fold by removing the van der Waals contact to the 5-position 
–CH3 group of SKA-111 (Figures 6B and 7). Mutating S181 
to a charged arginine or large phenylalanine also reduced 
SKA-111 potency presumably by “pushing” SKA-111 forward. 
Introducing even larger tryptophan or tyrosine residues had 
an interesting effect on KCa3.1 gating and resulted in channels 
that already produced large nA currents in the presence of 
only 250 nM free Ca2+, suggesting that these mutants are more 
sensitive to Ca2+ then the wild-type channel. We therefore 
did not use these two mutants for testing SKA-111 sensitivity. 
Mutating the other S45A helix residue, L185, that is in direct 
van der Waals contact with SKA-111 had a similar effect as 
mutating position 181. Replacing leucine 185 with a smaller 
alanine reduced SKA-111 potency by 7-fold, while substitution 
of a larger phenylalanine in 185-position produced an 8-fold 
reduction in potency (Figures 6B and 7). Introduction of even 
larger (W, Y) or charged residues unfortunately resulted in 
non-functional KCa3.1 channels that no longer respond to free 
Ca2+ concentrations as high as 10 µM (Figure 6B). Although 
it is not in direct contact with SKA-111 we also mutated the 
neighboring A184 position to F because our model suggested 
that a phenylalanine in this position would push the CaM-K75 
residue, that is contacting SKA-111 upwards. In keeping with 
this hypothesis, the A184F mutant was 9-fold less sensitive to 
SKA-111 than the WT KCa3.1 channel (Figures 6B and 7).
In order to more dramatically reduce SKA-111 sensitivity we 
next generated the double S181A-L185A mutant reasoning that 
it would disrupt both the van der Waals interactions SKA-111 
makes with the S45A helix. In keeping with this idea, the S181A-
L185A mutant produced a roughly additive effect when compare 
with the two single A mutations and reduced SKA-111 potency 
by 18-fold (Figures 6B and 7). In order to determine that this 
change in SKA-111 sensitivity is not caused by a reduced Ca2+ 
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sensitivity we performed in-side out recordings comparing 
the Ca2+ sensitivity of the S181A-L185A mutant with the WT 
KCa3.1 channel and found that mutant did not differ in its Ca2+ 
sensitivity (Figure 7C). As a further control experiment, we 
tested the sensitivity of a double “fenestration” mutation, T212F-
V272F, to SKA-111. We had previously generated this mutation, 
FIGURE 6 | Docking model of SKA-111 in the full-length KCa3.1 structure and mutational strategy. (A) Bottom and side view of the full-length KCa3.1 cryo-EM 
structure following Rosetta refinement in the Ca2+ free closed state (pdb: 6cnm) and Open state I (pdb: 6cnn). The channel is shown in gray, the CaM C-lobe in 
purple and the CaM N-lobe in yellow. Next to open state 1 we show a zoom out of the lowest energy docking pose of SKA-111 in the interface between the CaM 
N-lobe and the S45A helix interface. Hydrogen bonds are shown in black, van der Waals interactions are visualized in purple. For clarity, not all side chains of CaM 
residues within contact range of SKA-111 are explicitly shown. Please note the channel residues S181, A184 and L185. (B) Alignment of the S45A helix sequence 
in KCa2.1, KCa2.2, KCa2.3 and KCa3.1. Residues that were mutated are highlighted in yellow and the EC50 values for SKA-111 shown next to each mutant (for 
confidence intervals see Figures 7 and 8).
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which closes the KCa3.1 fenestration between S5 and S6 with 
two bulky aromatic residues without changing the biophysical 
properties of the channel when identifying the binding site of 
the dihydropyridine nifedipine in KCa3.1 (Nguyen et al., 2017). 
As expected, the double “fenestration” mutant was as sensitive to 
SKA-111 as the WT channel (Figure 7).
Why Did the S372R Mutation in Our 
Previous Study Have Such a Large Effect 
of KCa Activator Potency?
Taken together the above presented mutagenesis data suggest that 
the KCa channel activator SKA-111 is indeed binding in the interface 
between the S45A helix and the CaM N-lobe as hypothesized by Lee 
et al. (Lee and MacKinnon, 2018). However, we were still puzzled 
by the fact that we had previously seen such a strong reduction in 
potency for multiple KCa channel activators including SKA-31, 
SKA-111, EBIO and NS309, when mutating S372 in KCa3.1 or the 
corresponding S632 residue in KCa2.3 to arginine (Brown et al., 
2017). Based on the C-terminal crystal fragment we had believed this 
residue to be located at the back of the interfacial binding site pocket. 
In the full-length KCa3.1 structure S372 is located at the top of the 
C-terminal HC helix, which forms a coiled coil located at the center 
of the channel. As shown in Figure 8A, S372 is facing outward from 
this coil towards N42 in the CaM N-lobe and accepting a hydrogen 
bond from its NH2 group. Mutating S372 to a larger, charged 
arginine (Figure 8B)  in our Rosetta model of open state I “pushes” 
the outer edge of the CaM N-lobe 6.4 Å downwards, now resulting 
in a hydrogen bond with L39 in the CaM N-lobe and changing the 
shape and the volume of the interface pocket (see Figure 8C for 
an overlay of the WT and mutant channel). In keeping with this 
“distortion” of the interface pocket SKA-111 does not converge in the 
S372R mutant, while all top 50 lowest energy-binding poses virtually 
overlay in the WT channel pocket (Supplementary Figure 6). 
Interestingly, introducing the double AA mutation (S181A-L185A) 
into the S372R mutant, resulted only in small, but not statistically 
significant additional shift in the concentration-response curve of 
SKA-111 (Figure 8D).
DISCUSSION
We here attempted to perform structure assisted design of KCa2.2 
selective small molecule activators using the KCa2.2 CaM-BD/CaM 
FIGURE 7 | Mutations of S181 and L185 in the S45A helix disturb SKA-111 activity but not calcium gating. (A) Representative whole-cell WT and mutant KCa3.1 
currents with an intracellular free calcium concentration of 250 nM in the presence and absence of SKA-111. (B) Concentration–response for SKA-111 induced 
current activation: WT (EC50 = 146 nM, 95% CI: 99–193 nM), T212F-V272F (EC50 = 153 nM, 95% CI: 114–182 nM, P = 0.1017), S181A (EC50 = 1.012 µM, 95% CI: 
0.780–1.244 µM, P < 0.0001), A184F (EC50 = 1.326 µM, 95% CI: 1.205–1.447 µM, P < 0.0001), L185A (EC50 = 0.993 µM, 95% CI: 0.903–1.083 µM, P < 0.0001), 
S181A-L185A (EC50 = 2.654 µM, 95% CI: 2.619–2.624 µM, P < 0.0001). Whole-cell KCa3.1 currents were elicited by voltage-ramps from －120 to + 40 mV with 
an intracellular free calcium concentration of 250 nM. Data points are mean ± S.D. from 3–5 independent cells/recordings. The reported P values are for an extra 
sum-of-squares F test (GraphPad Prism5; GraphPad Software, La Jolla, CA) to compare the curves of KCa3.1 mutants to WT. (C) Inside-out calcium concentration-
response curves for WT KCa3.1 (EC50 = 437 nM, 95% CI: 353–521 nM, nH = 1.98) and the S181A-L185A double mutant (EC50 = 392 nM, 95% CI: 287-497 nM, 
nH = 1.39, P = 0.4951). Data points are the mean ± S.D. from 3–5 independent recordings. The calcium-sensitivity of the mutant is statistically not different from 
the WT KCa3.1 channel (P = 0.4951 in extra sum-of-squares F test).
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crystal structure. This structure seemed extremely attractive for a 
structure based approach because it had been repeatedly crystalized 
by multiple groups. The first structure of the KCa2.2 channel 
C-terminal calmodulin binding domain (CaM-BD) in complex 
with CaM was reported in 2001 at 1.6 Å resolution and showed an 
elongated, anti-parallel dimer of two KCa2.2 C-terminal 76 amino 
acid long fragments. On each of these channel pieces CaM was 
tightly bound with its C-lobe to two alpha helices connected by a 
turn from the same channel subunit and “grabbed” the free end of 
the fragment from the other subunit in the dimer with its N-lobe 
suggesting that CaM-BD dimerization might gate KCa2 channels 
(Schumacher et al., 2001). The same dimeric crystal orientation 
was afterwards repeatedly observed in structural studies addressing 
the mechanism of action of small molecule KCa channel activators 
and of PIP2 on KCa2.2 channel function (Zhang et al., 2012; Zhang 
et al., 2013; Zhang et al., 2014). Zhang et al. showed in several high-
resolution X-ray structures that the KCa activator EBIO, the more 
potent NS309, as well as several NS309 derivatives bind in the 
interface between the CaM N-lobe and the KCa2.2 CaM-BD (Zhang 
et al., 2012; Zhang et al., 2013; Nam et al., 2017). Independently of 
this work a group at Pfizer also crystallized the KCa2.2 CaM-BD/
CaM complex and showed the presence of two other KCa activators, 
riluzole and a CyPPA derivatives, in the interface between the CaM 
N-lobe and the channel CaM-BD (Cho et al., 2018). This interaction 
FIGURE 8 | Rosetta Model of the wild type KCa3.1 channel in open state 1 with serine in position 372 (A) and of the S372R mutant (B). Hydrogen bonds are visualized 
in black. (C) Overlay of the Rosetta models of the S45A helix/CaM N-lobe interface pocket in the wild type (yellow) and the S372R mutant shown in space fill. (D) 
Concentration-response curve for SKA-111 induced current activation: WT (EC50 = 146 nM, 95% CI: 99–193 nM), S372R (EC50 = 6.860 µM, 95% CI: 6.788–6.932 µM, 
P < 0.0001), S181A-L185A-S372R (EC50 = 8.876 µM, 95% CI: 8.652–9.100 µM, P < 0.0001). Data points are mean ± S.D. from 3–5 independent cells/recordings.
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was further confirmed by solution state NMR experiments 
demonstrating that riluzole and the CyPPA analog perturb the 
chemical shifts for both 15N-labeled CaM and 15N-labeled KCa2.2 
CaM-BD fragments (Cho et al., 2018). Moreover, our own previous 
molecular modeling studies using the KCa2.2 CaM-BD/CaM crystal 
structure to generate a homology model of the analogous binding 
pocket for the related KCa3.1 channel in order to explain the KCa3.1 
selectivity of our KCa activators SKA-111 and SKA-121 (Coleman 
et al., 2014), seemed in good agreement with experimental 
mutagenesis and structure-activity relationship observations for 
the SKA-type activators (Brown et al., 2017). As described above 
we were therefore very astonished when our computationally 
designed SKA molecules, which based on the Rosetta modeling 
work should have been both KCa2.2 selective and potent, showed 
such disappointing activity in electrophysiological experiments. 
By demonstrating that the C-terminal CaM-BD/CaM crystal is 
an artefact the full-length KCa3.1 structure (Lee and MacKinnon, 
2018) explained this conundrum for us. The study also provided 
us with a very testable structural hypothesis for an alternative KCa 
activator binding site in between the highly flexible CaM N-lobe 
and the S45A helix in the unusually long S4-S5 linker of KCa3.1.
We here tested this hypothesis from the MacKinnon laboratory 
and found that at least our KCa channel activator SKA-111 is indeed 
binding in the interface pocket between the S45A helix and the 
CaM N-lobe. Interestingly, while the channel residues implicated 
in SKA-111 binding, namely S181, A184 and L185 (Figure 9A), 
are now different, the residues in the CaM N-lobe (F19, I27, L32, 
M51, E54, M71, and K75) are the same residues as in our previous 
FIGURE 9 | Interactions between SKA-111 and residues in the KCa3.1 S45A helix (A) and the CaM N-lobe (B) interface pocket. Hydrogen bonds are indicated by 
black lines, van der Waals interactions are indicated by purple lines. (C) The KCa3.1-CaM channel complex seen from the intracellular side. The S45A helix/CaM 
N-lobe interface colored dark blue. Two other, potential binding sites for small molecules are highlighted with orange or sky-blue circles. The channel is shown in 
gray, the CaM C-lobe in purple and the CaM N-lobe in yellow.
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binding pocket (Figure  9B and Supplementary Figure 1). In 
both the “old” and the new binding pocket the amino group of the 
benzothiazole ring of SKA-111 forms two hydrogen bonds with 
M51 and E54 in the CaM N-lobe and makes nine van der Waals 
contacts with additional CaM residues. We suspect that these 
multiple, strong interactions with CaM are responsible for the fact 
that the benzothiazole riluzole and the structurally related EBIO 
and NS309 could be soaked into the C-terminal crystal where the 
highly flexible N-lobe of CaM had “grabbed” the only available part 
of the C-terminal helix that was not already occupied by the C-lobe. 
And as chance would have it the sequence in this part of the KCa2.2 
C-terminus also contains a serine and leucin, similarly spaced 
apart, creating a very similar environment on the channel side for 
additional van der Waals contacts. The fact, that the majority of the 
contacts that SKA-111 is making in the interface pocket between 
the S45A helix and the CaM N-lobe are with CaM are also in line 
with our findings that we could significantly alter SKA-111 potency 
by mutating KCa3.1 residues in the S45A helix but not render KCa3.1 
completely insensitive to its activating activity without rendering 
the channel non-functional through more drastic mutations.
We believe we have now identified the “correct” binding site for 
SKA-111 and related SKA compounds. However, since we only used 
mutagenesis in combination with functional electrophysiological 
recordings to confirm the binding site, there remains the caveat 
that we could have observed allosteric effects. It will therefore 
be important to perform additional experiments in future that 
demonstrate binding to the S45A helix for example with a photo-
affinity probe and to directly measure ligand binding affinities 
using surface plasma resonance, isothermal titration calorimetry 
or differential scanning fluorimetry. These experiments should be 
performed with physiological ligand concentrations and not with 
saturating concentrations as was the case in the above described 
crystallography and solution state NMR studies in order to avoid 
the identification of “non-physiological relevant” binding sites.
Based on the KCa3.1 structural model we would further like to 
hypothesize here that the cytoplasmic facing surface of KCa3.1 and 
the closely related KCa2 channels offer multiple binding pockets 
for positive and potentially also negative gating modulators. 
As visualized in Figure 9C in dark blue, the S45A helix/CaM 
N-lobe interface is present four times in the complex consisting 
of four KCa3.1 α-subunits and four CaM molecules. How many 
of these pockets can be occupied by a small molecule activator is 
currently unknown and we would like to posit that it is possible 
that the occupancy of these four pockets might differ between 
different activators molecules and different KCa channel subtypes. 
In addition to the S45A helix/CaM N-lobe interface, the SiteMap 
function of the Schrödinger Glide software identifies two other 
potential druggable sites in the cytoplasmic surface of KCa3.1 that 
could accommodate small molecules: one adjacent site located 
between the S45B helix and the HA helix in the C-terminus (orange 
circle in Figure 9C) and another site in the space between the 
CaM C-lobe and the HB helix in the C-terminus (sky blue circle 
in Figure 9C). Additional experimental and structural work will 
be necessary to determine if any, and how many, of these sites are 
targeted by positive or negative KCa channel gating modulators.
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